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Eqv migraine aura without headache, migraine equivalent
HA headache (no migraine)
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MU migraine with unclassified aura
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MwoA migraine without aura
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MIG
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1. INTRODUCTION
The recent progress of molecular genetics has widened horizons in many fields of
medicine. In 1993 the first genetic locus was linked to a migraine disorder, familial
hemiplegic migraine (FHM) (1), a rare autosomal dominant form of migraine with
aura. Later the gene, CACNA1A, was identified and shown to code for one of the
subunits of a voltage-dependent calcium (Ca2+) channel (2). This has stimulated
research on migraine pathophysiology and many new discoveries are anticipated in
the next few years.
Perhaps the most important lesson of the FHM-breakthrough was that hereditary
migraine, also on a broader scale, might be a disease caused by mutations in ion
channels, a ‘channelopathy’ (3, 4). Ion channels are important functional units of
all cells, having special importance in the central nervous system. They modify, among
other things, neuronal excitability (5, 6). Migraine patients are known to be ‘sensitive’
to many internal and external triggers (7, 8) and some of this hyperexcitability could
well be caused by dysfunctional ion channels (9). The uncovering of FHM has
provided new insight into the mechanisms leading to a migraine attack. This will
hopefully also lead to new modalities for the treatment of migraine in the future.
Especially new prophylactic medications are eagerly waited for.
In the current treatment of migraine, the big step forward has been the develop-
ment of the ‘triptans’ (10-12) i.e. migraine-specific drugs, which have improved the
life of many patients, especially those with the most severe attacks (13). The target of
the triptans, the serotonin system, is well known for its role in pain transmission (14)
in which ion channels have an integral modifying role. There could well be clinically
important secrets in the connection between the two recent success stories in the
migraine world, and patients and clinicians alike are eagerly waiting for what is to
come.
Much work is needed to make progress in the trail from genetics to the clinic, or
vice versa. The gap from the ion channel to the patient is wide. In Finland a system-
atic clinical project was started in 1993 to secure enough power for molecular genetic
analysis to locate new predisposing liability genes for migraine. Hundreds of patients
have been studied, families recruited and blood samples collected. Additional work
has been done to pinpoint possible candidate genes for the molecular geneticists. Ion
channels are obvious choices, but there are others, too. Migraine is, after all, a
neurovascular disorder (15) and vascular mechanisms should not be overlooked (16).
Endothelin-1 (ET-1), a potent vasoconstrictor first connected to migraine by Färkkilä
and colleagues in 1992 (17), is one of the many candidate genes related to the
regulation of vascular tone during migraine attacks. ET-1 has been associated with
vasospastic disorders (18) and could well modify attack characteristics, especially
during the aura phase of migraine.
The present study points out clinical observations on hereditary migraine in
Finland during the first years of the project. The eventual goal of the study is to
identify predisposing genes for migraine with and without aura. It is hoped that the
study will help to better understand migraine pathophysiology and subsequently to
develop new migraine treatments.
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2.1. Definitions and criteria of
migraine
The current understanding is that migraine
is a neurovascular disorder (15) character-
ised by neuronal aura symptoms and vascu-
lar headache. Since 1988 migraine is defined
by the criteria set by the Headache Classifi-
cation Committee of the International Head-
ache Society (IHS) (19). According to the
criteria migraine with aura is an  “idiopathic,
recurring disorder manifesting with attacks
of neurological symptoms unequivocally
localizable to cerebral cortex or brain stem,
usually gradually developed over 5-20 min-
utes and usually lasting less than 60 minutes.
Headache, nausea and/or photophobia usu-
ally follow neurological aura symptoms di-
rectly or after a free interval of less than an
hour. The headache usually lasts 4-72 hours,
but may be completely absent”. Correspond-
2. REVIEW OF THE LITERATURE
ingly migraine without aura is an “idiopathic,
recurring headache disorder manifesting in
attacks lasting 4-72 hours. Typical charac-
teristics of headache are unilateral location,
pulsating quality, moderate or severe inten-
sity, aggravation by routine physical activ-
ity, and association with nausea, photo- and
phonophobia”. Table 1 presents the current
classification and Table 2 the diagnostic cri-
teria. These criteria have been a major im-
provement for migraine research (20, 21) and
have been shown to perform adequately both
in science and in the clinic (22, 23). Perhaps
the best proof for the usefulness of the crite-
ria is that the triptans, migraine-specific
drugs, have been shown to perform equally
well in different countries in multicentre,
multinational, double-blind studies using
these criteria (11, 13, 21). Thus it seems that
study populations meeting the criteria have
been uniform across countries and continents.
Table 1. International Headache Society Classification of Migraine (reference 19)
1. MIGRAINE
1.1 Migraine without aura
1.2 Migraine with aura
1.2.1 Migraine with typical aura
1.2.2 Migraine with prolonged aura
1.2.3 Familial hemiplegic migraine
1.2.4 Basilar migraine
1.2.5 Migraine aura without headache
1.2.6 Migraine with acute onset aura
1.3 Ophthalmoplegic migraine
1.4 Retinal migraine
1.5 Childhood periodic syndromes that may be precursors to or
associated with migraine
1.5.1 Benign paroxysmal vertigo of childhood
1.5.2 Alternating hemiplegia of childhood
1.6 Complications of migraine
1.6.1 Status migrainosus
1.6.2 Migrainous infarction
1.7 Migrainous disorder not fulfilling above criteria
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Table 2. International Headache Society  Criteria for Migraine with and without Aura (19)
1.1 Migraine without aura
A. At least 5 attacks fulfilling B-D
B. Headache attacks lasting 4-72 hours
(untreated or unsuccessfully treated)
C. Headache has at least two of the following characteristics:
1. Unilateral location
2. Pulsating quality
3. Moderate or severe intensity (inhibits or prohibits daily activities)
4. Aggravation by walking stairs or similar routine physical activity
D. During headache at least one of the following:
1. Nausea and/or vomiting
2. Photophobia and phonophobia
E. At least one of the following:
1. History, physical- and neurological examinations do not suggest a secondary cause
of headache
2. History and/or physical- and/or neurological examinations do suggest such disorder,
but it is ruled out by appropriate investigations
3. Such disorder is present, but migraine attacks do not occur for the first time in close
temporal relation to the disorder
1.2 Migraine with aura
A. At least 2 attacks fulfilling B
B. At least 3 of the following 4 characteristics:
1. One or more fully reversible aura symptoms indicating focal cerebral cortical - and/
or brain stem dysfunction
2. At least one aura symptom develops gradually over more than 4 minutes or, 2 or
more symptoms occur in succession
3. No aura symptom lasts more than 60 minutes. If more than one aura symptom is
present, accepted duration is proportionally increased
4. Headache follows aura with a free interval of less than 60 minutes. (It may also
begin before or simultaneously with the aura)
C. Same as 1.1.E, see above
2.2. Clinical characteristics of
migraine with and without aura
The current IHS criteria describe well the
major features of migraine aura and headache
(Table 2).
2.2.1. Migraine aura
The migraine aura is exceptionally diverse
and is thoroughly analysed by Liveing and
later by Sacks (24, 25). According to the
IHS, migraine aura consists of homonymous
visual disturbances, hemisensory symptoms,
hemiparesis or dysphasia, or their combina-
tions. Gradual development, duration under
one hour and complete reversibility are char-
acteristic (19). Russell and Olesen, in 1996,
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found that in the general population migraine
aura is visual in 99%, sensory in 31%, aphatic
in 18% and includes motor disturbances in
6% of the patients. “The typical visual aura
starts as a flickering, uncolored, zigzag line
in the centre of the visual field and affects
the central vision. It gradually progresses to-
wards the periphery of one hemifield and
often leaves a scotoma. The typical sensory
aura is unilateral, starts in the hand,
progresses towards the arm and then affects
the face and the tongue. The typical motor
aura is half-sided and affects the hand and
arm”(26).
2.2.2. Migraine headache
The same Danish group has studied the preva-
lence of IHS-defined features of migraine
headache in the general population (Table 3)
(27). The table summarises perhaps the most
thoroughly studied characteristics of the
headache phase of IHS-defined migraine
published so far. Migraine headache is usu-
ally moderate or severe and lasts the whole
day, sometimes two to three days. It is typi-
cally unilateral, pulsating, and associated with
nausea, photophobia and phonophobia.
Physical activity usually makes it worse, and
often the patient has to lie down during the
attack. In severe attacks the patient may vomit
repeatedly. The usual notion is that the head-
ache is identical in migraine with and with-
out aura (28, 29).
2.2.3. Migraine attack
While aura and headache are the hallmarks
of migraine, the migraine attack can be seen
in a broader sense. Sacks describes five stages
in a typical migraine attack: initial excitement
(caused by a provocative stimulus), a state
of engorgement (prodromal symptoms), a
state of prostration (attack itself with head-
ache), a state of resolution (when the attack
ends either abruptly or gradually) and a state
Table 3. Prevalence of IHS Charateristics of Headache in Migraineurs by Russell and
Colleagues (27)
Migraine without aura Migraine with aura
Headache characteristic Men (%) Women (%) Men (%) Women (%)
N=197 N=145 N=92 N=64
Frequency 100,0 100,0 100,0 100,0
Duration 99,0 99,3 65,2 79,4
Severity 100,0 100,0 90,2 93,8
Pulsating quality 84,8 79,0 78,3 75,4
Location unilateral 48,2 64,3 55,4 64,1
Physical activity 98,0 95,8 87,0 80,0
Nausea 85,8 88,9 70,7 81,5
Vomiting 41,6 49,3 37,0 44,6
Photophobia 92,4 92,4 82,6 90,8
Phonophobia 78,7 85,4 64,1 78,5
The figures represent the proportion of patients (%) meeting the particular criteria defined by the International Headache
Society (IHS). N=number of patients
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of rebound (state of well-being after the at-
tack) (30). Selby has described migraine as
“a drama in three acts”, the acts being pre-
monitory symptoms, aura followed by head-
ache and finally attack termination with a
“hangover” (31). Blau (32) has also empha-
sised the dynamic nature and different phases
of migraine. Premonitory symptoms may
occur hours to a day or two before a migraine
attack (with aura or without aura) (19). They
usually consist of hyperactivity, hypoactivity,
depression, craving for special foods, repeti-
tive yawning and similar atypical symptoms.
Typical ‘hangover’ symptoms after the attack
include physical and mental fatigue, subdued
and depressed mood, impaired concentration,
reduced physical activity, and yawning (33).
2.3. Familial hemiplegic migraine
(FHM)
Recent progress in molecular genetics has
emphasised the importance of the clinical
characteristics of FHM. According to the
current classification (see Table 1) FHM is
an autosomal dominant form of migraine with
aura (19). As in migraine with aura, homony-
mous visual disturbances, hemisensory
symptoms, hemiparesis or dysphasia, or com-
binations of these, are typical. Gradual de-
velopment, duration under one hour, and
complete reversibility are characteristic of the
aura which is associated with headache.
Families with strikingly identical and some-
times long-lasting attacks have been de-
scribed (19). Table 4 presents the IHS crite-
ria of the entity. In addition to migraine aura
and headache, some patients have episodic
or progressive ataxia as part of their symp-
tomatology (34-36). Thus, the clinical char-
acteristics of FHM and the more common
forms of migraine (with and without aura)
are far from identical. On the other hand, in
FHM families there are also patients with
these common forms of migraine, and FHM
patients can also have attacks of “non-hemi-
plegic migraine” (36). It has been hypoth-
esised that FHM can be seen as a model for
studying migraine with and without aura.
Patients with FMH would thus represent the
most severe phenotype of these entities and
could assist greatly in uncovering their patho-
physiology (36).
2.4. Diagnosing migraine
Migraine is currently diagnosed according to
the IHS criteria (19). The criteria represent
the expert opinion of acknowledged clini-
cians on what is characteristic of migraine.
Table 4. International Headache Society Criteria for Familial Hemiplegic Migraine (19)
Description: Migraine with aura including hemiparesis and where at least one first degree
relative has identical attacks
Diagnostic criteria:
A. Fulfils criteria for  migraine with aura
B. The aura includes some degree of hemiparesis and may be prolonged
C. At least one first degree relative has identical attacks
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The criteria have been shown to be exhaus-
tive and valid in clinical practice (37, 38).
There are naturally also other ways to define
migraine (39, 40) and the IHS criteria have
also been criticised (41). Clearly, in clinical
practice, patients may have attacks that are
difficult to categorise strictly according to the
criteria. In all cases, regardless of the diag-
nostic criteria applied, the diagnosis is made
by a trained physician based on clinical ex-
amination and a clinical interview. The diag-
nosis can also be made based on migraine-
specific questionnaires in situations where a
visit to the physician can not be arranged or
is impractical.
2.4.1. Clinical diagnosis
The only method that formally fulfills the IHS
criteria for diagnosing migraine is a face-to-
face interview and a clinical examination
performed by a neurologist (42). Besides the
history given by the patient, there is no clini-
cal, laboratory, radiological or other study
or test that assists in the diagnosis. Thus the
clinical experience and practical skills of the
physician are the most essential diagnostic
tools in diagnosing migraine.
2.4.2. Questionnaire-based diagnosis
In numerous epidemiological studies, mi-
graine has been diagnosed based on the pa-
tient’s replies to questionnaires. Diagnosing
diseases with self-administered question-
naires has both advantages and disadvan-
tages, compared to a clinical interview. Self-
administered questionnaires are usually in-
expensive, able to reach remote populations,
allow for reflexion and search for informa-
tion, put little pressure on participation, have
no interviewer effect, and can bring up bet-
ter information to sensitive questions (43).
On the other hand, the questionnaires must
be short and highly structured, there are few
possibilities for detecting misunderstand-
ings, non-linear data collection is difficult,
response rates are often low, and there is no
guarantee of getting a response from the
proper person (43). Questionnaires on head-
ache and migraine have been validated by
comparing self-administered questionnaires
with clinical examinations as the ‘golden
standard’. Table 5 presents predictive val-
ues and agreement (kappa-value) rates be-
tween questionnaire-based and clinical in-
terview-based diagnoses of selected valida-
tion studies (44-52). The studies differed in
their methodology and can not be compared
directly, but they do give an overview of
the validity of the different questionnaires
used. It is especially important to choose
the study population of validation studies
correctly. Agreement may tend to be over-
estimated in studies based on interviews of
clinical samples instead of using random
samples of the population (52). On the other
hand, the final evaluation of validity and re-
liability of any questionnaire is how it per-
forms in the population for which it is de-
signed for (43). Thus, questionnaires for
the general population should be validated
in the general population and questionnaires
for the clinical patient in the clinic. As
shown in Table 5, and also in other studies
(53, 54), with a proper design and study
population, migraine can be diagnosed reli-
ably with a questionnaire.
The well-specified and simple nature of
the current IHS criteria will also guide in the
development of questionnaires. Despite this,
some studies have revealed major flaws in
questionnaire-based diagnosing (44, 53, 55).
The main obstacles have been poor response
rates (55), inability to differentiate subgroups
of migraine (53) and difficulties in differen-
tiating different forms of headache (44). To
overcome these deficiencies, Olesen has pro-
posed a procedure in which the migraine di-
agnosis, in large epidemiological studies,
starts with a screening questionnaire, fol-
lowed by a telephone interview, and finally a
definite diagnosis is established after a face-
to-face interview and a neurological exami-
nation (42).
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2.5. Epidemiology of migraine
The literature dealing with the epidemiology
of migraine is substantial. Table 6 presents
selected observations concerning migraine
prevalence and incidence.
2.5.1. Prevalence
Migraine is a very common disorder. With
the modern criteria, life-time prevalence for
any type of migraine in the general popula-
tion is about 10% for men and 25% for
women (49, 56). Life-time prevalence is
roughly 5% for migraine with aura and 10%
for migraine without aura. Both types of mi-
graine are overrepresented in females, and
more so in migraine without aura (28, 57).
Ulrich and colleagues studied life-time preva-
lence of migraine in twins in the general popu-
lation (58). The prevalence for migraine with
aura was 8% for women and 7% for men.
For migraine without aura the correspond-
ing figures were 19% for women and 7%
for men.
Table 5. Conditional Probabilities and Agreement Between Questionnaire-based and Clinical
Interview-based Diagnoses of Migraine in the Literature
Author Respondents Sensitivity Specificity Negative Postitive Kappa (95% CI)
N predictive  predictive
value value
Rasmussen,
Denmark, 1991 (44) 712 0,51 0,92 0,93 0,50 0,43 (0,32-0,54)
Galiano,
Spain, 1994 (47) 34 1,0 0,94 1,0 0,90 0,71
Pereira-Monteiro,
Portugal, 1992 (45) 205 0,41 0,92 0,84 0,59 0,37 (0,20-0,55)
Lainez,
Spain, 1994 (46) 316 0,34 0,86 0,75 0,51 0,22 (0,10-0,32)
Wong,
Hong Kong, 1995 (48) 101 0,73 0,86 0,56 (0,36-0,76)
Russell,
Denmark, 1995 (49) 727 0,89 0,93 0,77 (0,71-0,83)
Sakai,
Japan, 1996 (50) 102 0,80 0,96 0,98 0,67 0,56
Hayran,
Turkey, 1999 (51) 294 0,68 0,91 0,95 0,53 0,52
Hagen,
Norway, 2000 (52) 167 0,69 0,89 0,78 0,84 0,59 (0,47-0,71)
N=number of respondents, CI=confidence interval
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The same migraine patient can suffer
from both migraine with and without aura.
A common estimate is that 3/4 of all migraine
patients have migraine without aura, 1/3 mi-
graine with aura and up to 1/3 have both mi-
graine with and without aura (4). One-year
prevalences in Denmark are also shown in
Table 6 (59).
2.5.2. Incidence
The age of onset is younger for men than for
women and the first symptoms of migraine
with aura occur at a younger age than of
migraine without aura. Table 6 summarises
the peak age- and gender-specific incidences
from USA (60).
Table 6. Epidemiology of  Migraine
Type of migraine: Lifetime prevalence (%)
women  men
Migraine, any 25 10
Migraine with aura 8 7
Migraine without aura 19 7
Women:
One-year prevalence Mean age of population
(%)  (years)
Migraine with aura 11 46.0
Migraine without aura 5 43.7
Women with: Peak incidence per Age
1000 person-years (years)
Migraine with aura 14,1 12-13
Migraine without aura 18,9 14-17
Men:
One-year prevalence (%) Mean age of population
(years)
Migraine with aura 2 49.5
Migraine without aura 3 42.3
Peak incidence per Age
1000 person-years (years)
Migraine with aura 6,6 5
Migraine without aura 10,0 10-11
References: 28, 49, 56–60
19
2.6. Differential diagnosis of
migraine
The migraine has to be differentiated from
disorders presenting with neurological aura-
like symptoms or headache as part of their
symptomatology.
2.6.1. Migraine aura
The differential diagnosis of migraine aura
concerns mainly cerebrovascular diseases
and epilepsy (61). The differentiation de-
pends on a thorough history which pays at-
tention to the recurring nature and duration
of migraine aura. Familiarity with the com-
plexity and sequence of migraine aura will
also help in the differential diagnosis (62).
Migraine is essentially a recurring con-
dition, as underlined also by the IHS criteria
(Table 2) (19). While one aura does not make
a migraineur, recurrent auras do. This is es-
pecially important in acute situations; the first
migraine aura should always be studied care-
fully to rule out secondary (and dangerous)
vascular causes of migraine-like symptoms.
The migraine aura typically ‘builds up’,
expands and migrates in the visual field last-
ing 5-20 minutes (19). If the symptoms are
sudden, exclusively negative and maximal
instantly at onset, vascular events other than
migraine should be suspected. When the pa-
tient is elderly or has vascular risk factors,
caution is recommended as well (63). Con-
vulsions and loss of consciousness are not
usually part of migraine, and if such symp-
toms appear, epilepsy should be ruled out
(25). Epileptic phenomena are usually much
more abrupt than the gradually spreading
migraine aura (25).
Migraine aura is characterised by its
complex and diverse nature. The sequence
of migraine is part of the complexity and
helps to differentiate migraine from many
other conditions. Various visual, sensory,
motor, speech and balance disturbances can
be present at the same time or follow each
other. They are usually both positive (i.e.
zigzag lines) and negative (hemianopia). If a
combination of premonitory, aura, headache
and postdromal phases repeatedly follow
each other in sequence, the diagnosis of mi-
graine is secure (32, 62).
Some rare neurological disorders also
have to be considered in the differential di-
agnosis. Aura-like symptoms very similar, if
not identical, to migraine aura are part of the
MELAS (64, 65) and the CADASIL syn-
dromes (66) (MELAS = mitochondrial en-
cephalopathy with lactic acidosis and stroke-
like episodes; CADASIL = cerebral auto-
somal dominant arteriopathy with stroke-like
episodes and leucoencephalopathy). If there
is suspect family history or additional clini-
cal characteristics (accompanying strokes,
depression, dementia) these entities should
be ruled out with appropriate studies. Mag-
netic resonance imaging (MRI) is clearly the
best neuroradiological examination when
migraine is only one component of the spec-
trum of symptoms (67, 68). Also symptoms
associated with amyloid angiopathy can re-
semble migraine aura (69), and if this condi-
tion is clinically suspected (typical charac-
teristics are intracerebral haemorrhages
(ICH), strokes or transient ischemic attacks
(TIAs), dementia) neuroradiology with MRI
is indicated (70).
2.6.2. Migraine headache
Headache is usually the primary complaint
that brings a migraineur to visit a physician.
This can be challenging for the physician
because migraine can resemble a vast number
of conditions presenting with headache. Ta-
ble 7 shows some of the most important dis-
orders listed by Campbell and Sakai (61).
In acute cases migraine has to be distin-
guished from vascular headaches secondary
to cerebrovascular diseases. Subarachnoid
haemorrhage (SAH) is the most important
differential diagnostic entity (71). Contrary
to SAH migraine is a recurrent disorder. Thus,
until several attacks (five according to the
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criteria) have occurred, SAH should be ruled
out appropriately (adequate history and clini-
cal examination; computed tomography (CT)
and cerebrospinal fluid analysis, when indi-
cated). ICH (72, 73), ischemic stroke (74),
carotic dissection (75) and sinus thrombo-
sis (76) are also important differential diag-
nostic possibilities in emergency situations.
If the headache is chronic, lasting weeks
to months, migraine has to be differentiated
from tension-type headache (77), analgesic
abuse and many secondary headaches (61).
Again adequate history and clinical exami-
nation usually lead to correct diagnosis. The
features most predictive of migraine, when
compared to tension type-headache, are nau-
sea, photophobia, phonophobia, and exacer-
bation by physical activity (78). If there are
focal symptoms (not meeting the aura crite-
ria), or signs in neurological examination
neuroradiology is indicated (79), with con-
trast enhanced CT or preferably with MRI.
If the neurological status is normal with no
anamnestic focal symptoms the yield of
neuroradiology in this clinical setting is mini-
mal (80).
2.7. Pathophysiology of migraine
The key elements in migraine pathophysiol-
ogy are theories explaining how the attacks
start, where the ‘migraine generators’ reside,
what causes the migraine aura and migraine
headache, and why the aura so often leads to
a headache.
2.7.1.    Attack onset
Migraine has been considered as a state of
neuronal hyperexcitability relating to both
Table 7. Causes of Headache in the Differential Diagnosis of Migraine  (61)
Cerebrovascular Nonvascular Chemical, Cranium, neck, Other
disorders intracranial metabolic, eyes, and nose
disorders endocrine
abnormalities
Transient ischemic Beningn intracranial Nitrites, nitrates Arnold-Chiari Epilepsy
attacks hypertension malformation
Cerebral infarction Low CSF pressure Other Cervical spine Trauma
vasodilatators abnormalities
Cerebral haemorrhage Intracranial Hypoxia Purulent sinuitis Other primary
neoplasm headaches
Subarachnoid Hypoglycemia Sinus and base of Fever
haemorrhage skull neoplasms
Intracranial hematoma Dialysis Glaucoma, refractive Systemic
errors disease
Intracranial aneurysm Hypercarbia Tolosa-Hunt
and AVM syndrome
Arterial dissection Raeder’s syndrome
carotid or vertebral
Venous thrombosis
Arterial hypertension
Cranial vasculitis
CSF=cerebrospinal fluid, AVM=arteriovenous malformation
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genetic and environmental factors (81, 82).
It is believed that anyone can have a migraine
attack, but only migraineurs are liable to re-
current attacks (4, 83). There is evidence that
the brainstem with its wide connections is at
the heart of migraine. Diener and colleagues
have been able to show activation of
brainstem centres with positron emission to-
mography (PET) during migraine attacks
without aura. The ‘migraine generator’ is
hypothesised to be located in these centres
(84, 85). The serotonergic nucleus raphe dor-
salis (NRD) and the noradrenergic locus
coeruleus (LC) are anatomically very near
these activation centres described by Diener
and coworkers and they are currently con-
sidered as “the brainstem centres of migraine”
(85). These centres could play a role both in
the onset of attacks and in their prolongation.
The application of electrodes (to treat intrac-
table pain) near these centres can cause mi-
graine-like headaches in patients with no his-
tory of migraine (86). These centres have
extensive connections in the central nervous
system, and when activated, are thought to
lower the threshold for an attack (87-89). The
occipital lobes (where the visual aura is gen-
erated) seem most vulnerable to this
brainstem-driven hypersensitivity (90, 91). In
addition, both NRD and LC have well estab-
lished connections with the hypothalamus
which may account for premonitory symp-
toms (yawning, craving for food, thirst) be-
fore the main attack (92, 93). Genetic factors
(such as gender) form the basis underlying
these hypersensitive brainstem pathways, but
any factor, inherited or acquired, that affects
the network at different time points can
change the probability for attack onset (fac-
tors such as stress, emotional state, menstrual
cycle, pregnancy, medications, alcohol, etc.).
For example, stress, a common provoker of
migraine, can activate the brainstem via the
orbitofrontal cortex, and thus set the attack
in motion (83). Along with the unstable
aminergic pathways, many factors have been
hypothesised to contribute to the migraine-
related ‘hypersensitivity’: e.g. mitochondrial
defects (94), magnesium deficiency (95),
dysfunctional ion channels (2, 96), increased
membrane instability (82, 97), central
sensitisation of trigeminal fibers (98). Many
of the listed mechanisms are more likely con-
tributory than exclusive and together form
the multifactorial basis of migraine.
2.7.2. Migraine aura
Migraine aura is believed to be caused by a
phenomenon similar to “spreading depres-
sion” described by Leao already in 1944 (99,
100). The phenomenon, an innate feature of
the rodent brain, is believed to occur also in
humans (101). It could represent the expres-
sion of neuronal hyperexcitability related to
migraine. According to this theory, when the
human cortex is activated, a wave of neuro-
nal excitation, followed by depression, starts
to spread along the cortex and manifests it-
self clinically as migraine aura (102, 103).
Many unspecific events and causes can put
this phenomena in motion and start an attack.
The occipital cortex is especially sensitive to
spreading depression, which would explain
why visual fortification spectra is the hall-
mark of migraine (81, 104). Neuronal phe-
nomena are followed by vascular changes
(105-107) causing “spreading oligemia”
(108-110), and in exceptional circumstances
even ischemia, leading rarely to strokes (111,
112).
2.7.3. Migraine headache
After the migraine attack is underway, the
‘vascular’ headache of migraine usually su-
pervenes. The part of the trigeminal nerve
innervating cranial vasculature is at the heart
of the theory, explaining the migraine head-
ache (15). This trigeminovascular system,
when activated (e.g. by spreading depres-
sion), causes the blood vessels in the dura
mater to dilatate and neuropeptides to be re-
leased locally along the vessels. These
peptides cause further vasodilatation result-
ing in additional peptide release, and even-
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tually this vicious circle keeps the headache
going (113). Of the neuropeptides, calcitonin-
gene related peptide (CGRP), has been shown
to be elevated in the jugular blood of migraine
patients during the attacks (114, 115) and it
is a likely cause of this trigeminus-driven
‘neurogenic inflammation’ in the blood ves-
sels of migraineurs (116).
The trigeminoparasympathetic reflex is
another vasodilatating pathway thought to be
central in migraine (15). The afferent limb
of this arc is the trigeminal nerve, and the
efferent limb the facial/greater superficial
petrosal nerve of the parasympathetic nerv-
ous sytem.
In the periphery nitric oxide (NO), pro-
duced locally by the pulsating vessels, may
function as the common final pathway in the
initiation and maintenance of migraine head-
ache (117). Endothelin-1 (ET-1), a potent
vasoconstrictor, has been shown to be el-
evated early during migraine attacks, and is
a potential modulator of attacks (17, 118).
On the other hand, both a NO synthase in-
hibitor and an ET-1 antagonist (bosentan)
have failed in the treatment of migraine at-
tacks (119, 120).
2.7.4. Why aura leads to headache
The relationship between aura and how it
leads to headache has been difficult to ex-
plain. The current theory is that spreading
depression depolarises sensory nerve fibres
of the trigeminovascular system and sets up
a painful sterile inflammatory state around
the artery (105). Recently it has been hypoth-
esised that Ca2+ signals from the cortical pa-
renchyma may be transmitted to the pia-
arachnoid by gap-junction communication or
extracellular movement of adenine triphos-
phate (ATP), and that this could induce some
of the neurovascular changes in migraine
(121). In addition, recent studies with func-
tional magnetic resonance imaging (fMRI)
have shown aura-related activation of
brainstem centres nucleus ruber (NR) and
substantia nigra (SN). Aura-induced dys-
function of these centres could then play a
role during migraine headache and headache-
associated symptoms (nausea, vomiting,
dysautonomia) (122). Thus the connection
between migraine aura and headache has been
hypothesised to be both local (aura-induced
trigeminovascular neurogenic inflammation)
and central (dysfunction of brainstem cen-
tres).
2.7.5. Autonomic nervous system in
migraine
The autonomic nervous system (ANS) is
clearly involved in the migraine cascade with
symptoms such as nausea and vomiting,
among others. Sacks has seen the whole mi-
graine attack as characterised by “protracted
parasympathetic tonus”, preceded and fol-
lowed by opposite sympathetic activation
(123). Welch stressed the importance of the
sympathetic, noradrenergic arm of the auto-
nomic nervous system (83). Havanka-
Kanniainen proposed that both sympathetic
and parasympathetic dysfunction are in play
(124). The complex nature of the migraine
attack and various symptoms that can be re-
lated to the ANS make studies difficult to
interpret and firm conclusions regarding the
pathophysiology of migraine related to the
ANS are still elusive.
2.7.6. Serotonin in migraine
Serotonin (5-HT) has long been implicated
in migraine pathophysiology (125, 126) and
currently the most effective migraine drugs,
the triptans, have been shown to work
through 5-HT mechanisms (10). 5-HT may
play a role in both vascular and neuronal as-
pects of migraine. As a neurotransmitter, 5-
HT is predominantly inhibitory (127) and
modulates pain perception in the brainstem
(128). It is also vasoactive and can both con-
strict or dilatate blood vessels, depending on
the circumstances (vessel tone, diameter,
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vascular bed, species, administration route)
(129). Migraine has been seen as a chronic
systemic 5-HT deficiency, which predisposes
patients to painful headache attacks (130).
The triptans work by stimulating the 5-HT
system. The serotonin 5-HT
1D/ß
 receptors
(10) are specific targets for the triptans. The
5-HT
1ß
 receptor mediates mainly vasocon-
striction while the 5-HT
1D 
receptor reduces
pain transmission in the trigeminal nerve
(131, 132). 5-HT has wide spread effects
also outside the central nervous system. Se-
rotonin-packed platelets have long been im-
plicated in migraine pathophysiology (126).
Most likely the abnormalities observed in the
platelets (overall and enzyme activity,
serotonergic function, cell signaling) are sec-
ondary in the migraine cascade (133, 134),
but they might still be important in the rare
instances when migraine has caused a stroke
(134, 135).
2.7.7. Dopamine in migraine
Although the current research focus has been
on 5-HT, also dopaminergic effects are likely
to have an important modulating role in mi-
graine. Many migraine symptoms can be con-
sidered dopaminergic (yawning, nausea, vom-
iting) and dopamine antagonists are widely
used in the treatment of migraine (136). Re-
cently, activation of the dopaminergic substan-
tia nigra (SN) (along with another brain stem
centre, nucleus ruber (NR) has been observed
during migraine attacks with fMRI (122, 137).
The role of the dopaminergic system in mi-
graine needs further clarification. Lance and
Goadsby have concluded that available infor-
mation, in 1998, points to dopamine deficiency
with supersensitivity of dopamine receptors
(89) in migraine.
2.8. Treatment of migraine
The treatment of migraine can be divided into
acute and prophylactic treatments. Acute
(abortive) treatment is used to stop migraine
during the attacks, and prophylactic (preven-
tive) treatment attempts to decrease attack
frequency. The emphasis of this review is on
the medications widely used in Finland (Ta-
ble 8).
Table 8. Commonly Prescribed Migraine Medications in Finland
Acute treatment Prophylactic treatment
ASA ß- blockers:
Paracetamol      propranolol
NSAIDs      metoprolol
Triptans:      bisoprolol
     sumatriptan Amitriptyline
     naratriptan Valproate
     zolmitriptan Verapamil
     rizatriptan
Ergotamine
ASA=aspirin
NSAIDs=nonsteroidal anti-inflammatory drugs
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2.8.1. Acute treatment
The acute treatment of migraine is tailored
to the individual patient (138). If simple oral
analgesics (aspirin (139, 140) or paraceta-
mol) are efficient, they are widely used (141,
142). Nonsteroidal anti-inflammatory drugs
(NSAIDs, e.g. ibuprofen (143, 144),
tolfenamic acid (145, 146), naproxen sodium
(147) are a therapeutic option if simple anal-
gesics do not work (148). The addition of
metoclopramide increases efficacy and oral
absorption (149-151). If needed, alternative
routes of administration should be considered
to bypass gastroparesis and vomiting associ-
ated with migraine. The rectal, nasal or
parenteral routes might thus be preferable to
the oral (79, 142). Adequate dosing of anal-
gesics or NSAIDs is important (152).
If these measures are not adequate, mi-
graine-specific triptans, suma- (153-155),
nara- (156), zolmi- (157), riza- (158), or
eletriptan (159, 160), are widely used (141).
These drugs have proven to be a major ad-
vance in the treatment of migraine in the past
few years. Subcutaneous sumatriptan has a
success rate of about 80% within one hour
and 86% within two hours in clinical trials
(161-163). Oral preparations (suma-, nara-,
zolmi-, riza- and eletriptan) have success rates
of about 60% in clinical trials (13).
Sumatriptan is available and effective also
as intranasal spray (164) and rectal supposi-
tories (165).
The use of ergotamine (141) has been
reduced after triptans became available, but
they are still preferred by an important mi-
nority of patients (166). Dihydroergotamine
(DHE) is also used to treat severe migraine
attacks in some countries (167, 168).
2.8.2. Prophylactic treatment
ß-adrenoreceptor-blockers (ß-blockers)
propranol and metoprolol (169, 170) and the
antiepileptic sodium valproate (171) have
been shown to be effective in migraine pre-
vention, and are considered widely as first
line therapy for migraine prophylaxis (4, 172,
173). Besides propranolol and metoprolol,
other ß-blockers can also be used (174). The
intrinsic sympathomimetic action (ISA) of
some ß-blockers seems to reduce therapeu-
tic efficacy, and preparations without ISA
should thus be used (141).
Antidepressant amitriptyline has also
shown efficacy (175) and is widely used in
Finland: it is supposed to work because it
effectively treats tension-type headache, and
decreases also concurrent migraine attacks (4).
The efficacy of antiserotonin drugs
(methysergide and pizotifen) and calcium an-
tagonists (flunarizine) has also been proven,
and they are used in some countries, as are
NSAIDs (176).
2.8.3. National guidelines for management
of migraine
Recently some national guidelines for man-
agement of migraine have been published
(148, 177, 178). These guidelines have been
formulated to state general principles of treat-
ment in order to improve quality of care and
allow for informed decision making by both
physicians and patients. Corresponding Finn-
ish guidelines are also expected to be pub-
lished shortly.
2.9. Genetics of migraine
2.9.1. Historical perspective
It has been known for centuries that migraine
tends to run in certain families, and many
studies have addressed the inheritance of
migraine. Still there is no consensus on the
mode of inheritance of the common types of
migraine, migraine with and without aura
(179). There are several reasons for this.
Firstly, migraine is so prevalent (59) that it
might occur in several family members just
by chance. Secondly, variable definitions of
migraine have been used because there is no
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simple ‘marker’ for migraine and the diag-
nostic criteria have changed from time to time
(19, 39, 40, 180). The family studies are also
demanding in that all family members should
be interviewed directly, migraine with and
without aura should be accurately differen-
tiated, and population-based cohorts should
be used instead of clinical patients (181).
2.9.2. Family studies
Two population-based studies have addressed
the heredity of migraine using the current IHS
criteria and making a distinction between
migraine with and without aura (181, 182).
Based on these studies, Russell and col-
leagues concluded that migraine is a heredi-
tary disease, that migraine with and without
aura are distinct entities, and that migraine
with aura is largely or exclusively determined
by genetic factors, whereas also environmen-
tal factors are important in migraine without
aura. Peroutka and Howell studied 255 pa-
tients who had migraine without aura accord-
ing to the IHS criteria, and found that in 91%
at least one of the parents had IHS migraine
(183). This can be taken to suggest a domi-
nant mode of inheritance. It is likely that a
syndrome as diverse as migraine is not in-
herited in any simple way (179) and, indeed,
segregation studies of migraine have pointed
to multifactorial inheritance (184).
2.9.3. Twin studies
Several twin studies have supported a strong
genetic component for migraine. Merikangas
reviewed twin studies comparing monozy-
gotic (MZ) and dizygotic (DZ) twins, and
concluded that about 50% of the predisposi-
tion to migraine can be considered heredi-
tary (179). Table 9 summarises probandwise
concordance rates and heritability figures
from seven large population-based twin stud-
ies (185-190). In a recent twin study involv-
ing MZ and DZ twins raised together and
apart, Ziegler et al. came up with an estimate
of 52% (191), which is probably the best her-
itability estimate of migraine to date.
Table 9. Population-based Twin Studies of Migraine
Population Author IHS Migraine        Probandwise concordance Heritability
sample type M Z DZ
USA Corey et al. (1991) (185) - Migraine 0.35 0.17 0.36
Norway Corey et al. (1991) (185) - Migraine 0.32 0.18 0.28
Sweden Larsson (1995) (186) + Migraine 0.48 0.31 0.39-0.58
Australia Merikangas et al. (1994) (187) + Migraine 0.44 0.24 0.36
Finland Honkasalo et al. (1995) (188) - Migraine 0.28 0.12 0.34-0.51
Denmark Gervil et al. (1999) (190) + MwoA 0.43 0.31 0.61
Denmark Ulrich  et al. (1999) (189) + MwA 0.34 0.12 0.65
MwoA=migraine without aura, MwA=migraine with aura, IHS+=a study using the IHS criteria for migraine,
IHS=a study using other criteria, MZ=monozygotic, DZ=dizygotic
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2.9.4. Molecular genetic studies
In recent years, molecular genetic studies
have provided new and important informa-
tion on the pathophysiology of migraine.
Gene loci relevant to migraine have been
found in chromosomes 19, 1, 11 and X (Ta-
ble 10). Mitochondrial DNA (mitochondrial
deoxyribonucleic acid, mtDNA) has also
been studied.
In 1993 the gene for FHM was linked to
chromosome 19 (1) and in 1996 the first gene
for FHM was found (2). The gene,
CACNA1A, codes for a subunit (alfa 1A
subunit) of a calcium channel (P/Q type volt-
age sensitive Ca2+ channel) and this discov-
ery has evolved theories of migraine as a
‘chanellopathy’ (4, 192), along with other
neurological ‘paroxysmal’ episodic maladies
such as hyperkalemic periodic paralysis (Na+
channel affected), hypokalemic periodic pa-
ralysis (Ca2+ channel), episodic ataxia 1 (K+
channel) and 2 (Ca2+ channel), spinocerebel-
lar ataxia 6 (Ca2+ channel), benign neonatal
familial convulsions (K+ channel), congeni-
tal myotonia (Cl- channel), congenital para-
myotonia (Na+ channel) and malignant hyper-
thermia (Ca2+ channel) (192).
In association analyses, the CACNA1A
gene has also been connected to migraine
with and without aura (96). In addition,
Nyholt and colleagues have been able to link
typical migraine in an Australian family to
chromosome 19p13, but evidence for genetic
heterogeneity was also discovered (193).
Linkage of FHM to chromosome 1 has
been observed by two groups (194, 195). The
gene (or genes) has not yet been identified.
The nearby calcium channel genes are among
the most studied candidate genes.
However, there are FHM families not
linked to either chromosome 19 or 1, and thus
at least a third gene locus for FHM exists
(194).
Heterogeneity is also very likely for the
more common entities, migraine with and
without aura (193, 196). The female prepon-
derance of migraine could suggest involve-
ment of the X-chromosome in migraine. In-
deed, Nyholt and colleagues have found, in
two large multigenerational migraine pedi-
grees, significant excess allele sharing of Xq
in typical familial migraine (196). Peroutka
and colleagues reported overrepresentation
of DRD2 IC allele of the D2 dopamine
receptor gene in chromosome 11 in patients
FHM Migraine with “Dopaminergic” CADASIL MELAS
and without aura migraine
Chromosome 19 CACNA1A (2)  CACNA1A (association) (96) NOTCH3 (97)
Chromosome 1 Unknown gene in 1q21-31 (194-195)
Chromosome X Xq (association) (196)
Chromosome 11 DRD2 (association) (197) DRD2 (association) (198)
Mitochondrial DNA point mutations(65)
FHM=familial hemiplegic migraine, CADASIL=cerebral autosomal dominant arteriopathy with stroke-like epi-
sodes and leukoencephalopathy, MELAS=mitochondrial encephalopathy with lactic acidosis and stroke-like epi-
sodes, CACNA1A=the gene for a subunit of a P/Q-type calcium channel, NOTCH3=the gene for CADASIL
DRD2=the gene for dopamine receptor D
2
, q=long arm of a chromosome
Table 10. Molecular Genetics of Migraine
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with migraine with aura (197). In Sardinia,
Del Zompo and colleagues demonstrated a
positive association between allele 1 of the
same dopamine receptor gene in migraineurs
with both yawning and nausea during the at-
tacks (198). Dopaminergic candidate genes
have thus also been in the spotlight.
Syndromes in which migraine is one
component of a wider spectrum of symptoms
include CADASIL and MELAS. CADASIL
is characterised by ischemic strokes, vascu-
lar dementia, mood disorders, severe depres-
sion, and migraine with aura (199, 200). In
1996 a NOTCH3 gene was identified in the
CADASIL critical region  (97). The function
of this gene is unknown, but it may have
something to do with the development of neu-
ronal synapses (201). Why CADASIL pa-
tients can also have migraine with aura-like
symptoms is unknown at the present time. A
broad spectrum of clinical syndromes is as-
sociated with mutations in mtDNA. Virtually
all patients with MELAS suffer from mi-
graine-like attacks. It is possible that at least
in some families migraine might be caused
or modified by mitochondrial defects (65).
2.9.5. Comorbidity
Migraine has been associated with many he-
reditary diseases and syndromes (202). The
similarities with epilepsy are obvious, but a
firm genetic conclusion on this relationship
can not yet be drawn (202). It is noteworthy
that several epilepsy syndromes have recently
been shown to be ‘chanellopathies’ (5). Sus-
pected comorbidity of migraine with psychi-
atric and psychological problems is also well
known (203). The involvement of serotonin
both in depression, anxiety and migraine is
interesting also from the genetic point of view
(179, 204). There is a rare but clinically im-
portant association between migraine and
stroke, especially in young women (112). The
pathophysiological mechanisms underlying
this comorbidity remain to be clarified.
By far the most usual disorder associ-
ated with migraine is tension-type headache
(37). This combination is extremely common
especially in specialised headache clinics
(205, 206). Such patients present regularly
with very frequent, even daily, headaches and
susceptibility to medication overuse (205,
207). Regular comorbidity of migraine and
tension-type headache has been detected also
in random, non-clinical, populations (208,
209). Despite the common co-occurrence, the
entities are widely considered to be
pathophysiologically distinct (210, 211). On
the other hand, some scientists consider mi-
graine and tension-type headache to repre-
sent different ends of a shared headache con-
tinuum (212-215). Migraine patients with
severe attacks would be on one end of the
continuum, and patients suffering from ten-
sion-type headache characterised by milder
attacks on the other end. Pathophysiological
and genetic mechanisms underlying the
comorbidity of migraine and tension-type
headache and the occasional transformation
of migraine into complex chronic headache
syndromes (207) still remain for the most
part to be resolved. Mechanisms related to
central sensitisation could play a role in such
instances (98, 216).
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3. AIMS OF THE STUDY
The present study is part of the Finnish Migraine Gene Project, which aims to locate
predisposing genes for migraine in the Finnish population. The specific aims of this study
were:
1. To develop a questionnaire for use in twin and family studies of migraine (Studies
I, II)
2. To study possible differences in clinical characteristics of migraine with and with-
out aura in a population-based cohort of twins (Study II)
3. To evaluate whether migraine is identical in both co-twins of migraine-concordant
monozygotic twin pairs (Study III)
4. To study the clinical characteristics and co-occurrence of migraine with and with
out aura in Finnish migraine families (Study IV)
5. To study whether familial migraine with typical migraine with and without aura is
linked to the locus of Familial Hemiplegic Migraine on chromosome 19p13
(Study V)
6. To investigate the potential role of endothelin-1 in migraine pathophysiology
(Study VI)
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4. THE PRESENT STUDY
4.1. General remarks
The present work consists of six clinical
studies, four of which (Studies I-IV) focus
on migraine symptomatology, one on a can-
didate gene locus (Study V), and one study
is biochemical (Study VI). All studies were
conducted at the Department of Neurology,
Helsinki University Central Hospital, Helsinki,
Finland, in 1993-1999. The linkage analysis
for Study V was performed at the Depart-
ment of Human Molecular Genetics, National
Public Health Institute, Helsinki, Finland, and
the biochemical analysis of ET-1 for Study
VI at the Department of Medicine, Helsinki
University Central Hospital, Helsinki, Finland.
All studies were approved by the Ethics Com-
mittee of the Department of Neurology, and
the participants gave their written informed
consent for the studies, according to the
Declaration of Helsinki.
4.2. Diagnostic categories
The studies used the IHS-defined categories
of migraine with two exceptions. First, in the
questionnaire-based studies (Studies II,III,
IV), for the patients having attacks with aura
and headache, in which headache fulfilled the
IHS criteria but aura did not, migraine with
unclassified aura category (MU), rather than
migraine without aura (MwoA), was used.
Second, in Studies II-III and V-VI the pa-
tients having aura in every attack and the
patients getting attacks with and without aura
were classified as MA. In the family study
(Study IV) the IHS criteria were applied fully,
and the patients with both kinds of attacks
were differentiated from the patients with ex-
clusively aural attacks. In Study IV also pa-
tients having migraine aura without head-
ache, migraine equivalent (Eqv), were dif-
ferentiated from other patients with aura. The
corresponding diagnostic categories and ab-
breviations are thus (see also Table 11):
Table 11. Abbreviations of the Diagnostic Migraine Categories in the Studies
Migraine Migraine with Migraine with Migraine with Migraine without
equivalent aura  and without aura aura
(aura without (aura always) aura not meeting
headache)  the IHS criteria
Study I (FMSQTW) MA MA MA MU MwoA
Study II MA MA MA MU MwoA
Study III MA MA MA MU MwoA
Study V MA MA MA MU MwoA
Study VI MA MA MA MU MwoA
Study I (FMSQFS) Eqv MwA MwA+MwoA MU MwoA
Study IV Eqv MwA MwA+MwoA MU MwoA
The MA category includes patients with IHS migraine with aura (including migraine equivalents) and patients with
migraine with and without aura, FMSQ
TW
=the Finnish Migraine Specific Questionnaire for Twin Studies, FMSQ
FS
=the
Finnish Migraine Specific Questionnaire for Family Studies.
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• Migraine aura without headache: Eqv (Study
I, IV)
• Migraine with aura: MwA (Studies I, IV)
• Migraine with and without aura:
MwA+MwoA (Studies I, IV)
• Migraine with aura, or, migraine with and
without aura: MA (i.e. patients with exclu-
sively aural attacks, or, patients who have
both aural and non-aural attacks) (Studies I,
II, III, V, VI)
• Migraine with unclassified aura: MU (all
Studies)
• Migraine without aura: MwoA (all Stud-
ies)
• Headache not meeting the IHS criteria for
migraine: HA (Study II)
• Patients without migraine (headache can be
present): NO
MIG
 (Study I)
• Patients with no headache (or migraine):
NoHA (Study II)
4.3. Development and principles of study
questionnaires
The original version of the Finnish Migraine-
Specific Questionnaire (FMSQ
o
) was used in
Study V, in 1993. The questionnaire was then
systematically developed in collaboration
with a panel of neurologists, molecular ge-
neticists and epidemiologists. Experience
from various migraine studies along with
feedback from migraine patients attending an
outpatient neurologic clinic helped to im-
prove the questionnaire further. The patients
were asked to complete the questionnaire and
to give suggestions for improvement. The
feedback received was then discussed with a
panel of neurologists in debriefing sessions,
and the questionnaire was modified accord-
ingly. An upgraded version of the question-
naire, the Finnish Migraine-Specific Ques-
tionnaire for Twin Studies (FMSQ
TW
) (Ap-
pendix 1), was completed in 1996 and used
in Studies II, III and experience from these
studies led to further improvements, and the
final version of the questionnaire, the Finn-
ish Migraine-Specific Questionnaire for Fam-
ily Studies (FMSQ
FS
) (Appendix 2).
The questionnaire was developed on the
basis of the criteria of the IHS (19). Particu-
lar attention was paid to aura description. A
brief description of the most characteristic
visual aura (hemianopia, scotoma, fortifica-
tion spectra, photopsia, visual blurring) was
given in the questionnaire. The patients could
then indicate which of these best described
their aura. In addition, they were asked to
describe the aura in their own words. The
percentage of migraine attacks with visual
aura was recorded. Other types of aura re-
corded were sensory, motor, hemisensory and
hemiparetic, as well as vertigo and speech
disturbances. Particular attention was again
paid to the patient’s descriptions of these.
Questions relating to headache and other as-
pects of migraine (premonitory symptoms,
provoking and relieving factors, hormonal
influences, diurnal variation in the onset of
attacks, and associated autonomic-nervous-
system symptoms) were included. The pa-
tients were asked whether they experienced
different kinds of headache attacks and, if so,
how they differed from one another. The
efficacies of different medications were re-
corded, paying special attention to the
triptans. The overall health of each respond-
ent was determined from the responses to
questions on major illnesses and health prob-
lems. Family histories relating to migraine
and stroke were also recorded.
The presence or absence of the IHS-de-
fined characteristics of migraine headache
and aura were noted in questionnaire replies,
and the patients were categorised according
to the criteria (Table 2). No uncertain diag-
nosis was approved in the case of incom-
pletely filled questionnaires. In all uncertain
cases, a clinical interview (by telephone or
during a visit to the clinic) was arranged.
4.4. Validation of the study
questionnaires (Studies I, II)
Two separate questionnaires were analysed
and validated during the course of the stud-
ies: the FMSQ
TW
 and FMSQ
FS
.
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4.4.1. The Finnish Migraine-Specific
Questionnaire for Twins (FMSQ
TW
)
4.4.1.1. Subjects and methods
Consecutive migraine patients attending an
outpatient neurologic clinic in Helsinki, Fin-
land, were invited to take part in the valida-
tion study of FMSQ
TW.
 Patients were re-
cruited until 10 were clinically diagnosed
as having migraine with aura and 10 mi-
graine without aura (Table 12, Study I). The
patients were asked to complete the ques-
tionnaire later at home. The questionnaire
diagnosis was undertaken on the basis of the
questionnaire replies by a neurologist una-
ware of the clinical diagnosis reached.
Agreement between the two sets of diag-
noses was compared.
4.4.2. The Finnish Migraine-Specific
Questionnaire for Family Studies (FMSQ
FS
)
4.4.2.1. Subjects and methods
The FMSQ
FS
 was validated in two parts. The
first part analysed the questionnaire pre-
sented to clinical migraine patients. One
hundred consecutive clinically diagnosed
migraine patients attending an outpatient
neurologic clinic in Helsinki, Finland, were
invited to participate (Table 12, Study I).
These 100 patients completed the question-
naire at home. The questionnaire diagnosis
was undertaken on the basis of the ques-
tionnaire replies by another neurologist una-
ware of the clinical diagnosis reached.
Agreement between the two sets of diag-
noses was compared.
In the second part, consecutively identi-
fied families with a strong family history of
migraine (= 4 migraineurs in the family) were
involved. Family members, migraineurs or
non-migraineurs, were asked to complete the
questionnaire and mail it to one of the study
neurologists. One hundred consecutively re-
turned questionnaires were analysed; the cor-
responding family members were also in-
cluded. A migraine diagnosis was made on
the basis of the questionnaire replies. The 100
participants were then contacted by telephone
for a clinical interview. All telephone inter-
views were made by the same neurologist.
Based on these interviews, migraine was di-
agnosed in accordance with the IHS criteria.
The neurologist was unaware of the question-
naire diagnosis reached at the time of the tel-
ephone contacts. Agreement between the two
sets of diagnoses was compared.
Table 12. Subjets in the Studies
Study Patient number Gender Female to male Age of participants
N F/M ratio years
F:M mean (SD, range)
Study I 214 174F/40M 4.4 39.8 (16.4, 6-80)
Study II 805 670F/135M 5.0 44.9 (6.5, 36-68)
Study III 102 92F/10M 9.2 44.5 (7.2, 36-68)
Study IV 1000 730F/230M 3.2 43.1 (18.2, 6-91)
Study V 61 32F/29M 1.1 50.0 (20.0, 9-89)
Study VI 31 29F/2M 14.5 42.0 (9.3, 23-56)
N=number of patients, F=female, M=male, SD=standard deviation
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4.5. Clinical characteristics of
migraine in a population-based twin
sample and in migraine-concordant
monozygotic twin pairs
(Studies II, III)
4.5.1. Subjects and methods
The twin studies are based on the older part of
the Finnish Twin Cohort (217), which consists
of same-sexed Finnish twins born before 1958
and alive in 1967. The twins have been fol-
lowed up with questionnaires in 1975, 1981
and 1990. The 1981 and 1990 questionnaires
formed the basis, and all twins who had a set
diagnosis of migraine or self-reported headache
with a frequency greater than once a month
were listed. There were altogether 865 pairs
concordant for these criteria. Twins born be-
fore 1930, deceased since the 1990 study, liv-
ing abroad, or speaking Swedish as their mother
tongue, or taking part in a parallel hyperten-
sion study, were not included. This reduced the
available twin pairs to 509 (Tables 12-13).
FMSQ
TW
 was mailed to these 1018 individu-
als. The clinical characteristics of migraine
were analysed on the basis of the questionnaire
replies. 248 twins with undiagnostic or incom-
pletely filled questionnaires were contacted by
telephone by a study neurologist to define the
diagnosis. In Study III only those MZ twin
pairs (51 pairs) in which both co-twins were
subsequently diagnosed as having migraine
were analysed further.
4.5.1.1. Ascertainment of zygocity of the
twins (Study III)
The zygosity of all twins in the Finnish Twin
Cohort was originally determined with a
questionnaire method (218). To further test
the questionnaire method employed, all MZ
(zygosity based on questionnaire) aura-dis-
cordant twin pairs (pairs with one MA and
one MwoA twin, MA-MwoA pairs, alto-
gether 12 pairs) were genotyped. This was
done with five highly polymorphic fluores-
cence labeled DNA markers which were
D2S1790, D7S1805, D12S1045, D17S928,
and D19S246 (from the set of the Coopera-
tive Human Linkage Center). EDTA blood
samples were collected, and genomic DNA
extracted by standard procedures (219). The
markers were analysed using PCR (Polymer-
ase Chain Reaction) and gelelectrophoresis
by ALFexpress (Pharmacia Biotech, Uppsala,
Sweden).
4.6. Familial migraine with and
without aura (Study IV)
4.6.1. Subjects
In the family study consecutively identified
families with at least four members who were
affected by migraine were analysed. The
families were recruited from patients attending
two headache clinics in Helsinki and Kemi,
Table 13. Compilation of the Participating Twins in the Studies II and III
Twins from the Finnish Twin Cohort Individual twins Twin pairs
N N
All twins in the older part of the Finnish Twin Cohort 34000+ 17000+
Concordant for the incluson criteria 1730 865
Concordant and available for the study 1018 509
Returned the study questionnaire 805 (79.1%) 349 (68.6%)
MZ and returned the study questionnaire 239 (78.6%) 107 (70.4%)
MZ=monozygotic, N=number of twins or twinpairs, response rates in parentheses, the older part of the Finnish
Twin Cohort consists of the same-sexed Finnish twins born before 1958 and alive in 1967 (over 17000 twin pairs)
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Finland. Two neurologists were in charge of
the recruitment. When a member of the fam-
ily, i.e. the index case, was clinically diag-
nosed by a neurologist as suffering from mi-
graine, he or she contacted all the other mem-
bers of the family believed to suffer from
migraine and asked whether they would be
willing to participate in the study. If at least
three possible migraineurs were willing to
take part, the FMSQ
FS 
was mailed to each of
them, and to their parents and siblings. The
participants were then recruited until 1000
first family members had been diagnosed as
having migraine based on the returned ques-
tionnaires (Table 12, Study III). At this time
point altogether 210 migraine families had
participated in the study.
4.6.2. Methods
The clinical characteristics of migraine were
analysed on the basis of the questionnaire
replies. Four clinical indices were calculated,
reflecting migraine symptoms and severity.
The indices are based on the clinical experi-
ence of the neurologists involved in the Finn-
ish Migraine Gene Project and are intended
to assist in the clinical analysis of migraine
patients. They are not intended to be used in
clinical practice. The indices enable quanti-
tative analysis of migraine characteristics and
assist in comparisons between different
subtypes of migraine.
1. The aura index is designed to reflect the
occurrence of migraine aura throughout the
life-time of the patient. The index can range
from 0 (no aura) to 50 (for details see Table
14).
2. The index for IHS headache is designed to
reflect how precisely the IHS headache cri-
teria were met. One point was given for each
variable defined in the IHS classification
(headache frequency, headache duration, uni-
lateral headache, pulsating headache, mod-
erate or severe intensity, aggravation of head-
ache by physical activity, nausea, vomiting,
photophobia, phonophobia). The index (sum
of the given points) is referred to as the ‘IHS
score’. The index can range from 0 (no IHS
variable identifiable) to 10 (all IHS variables
identifiable).
3. The index for characteristics associated
with migraine is designed to reflect the oc-
currence of symptoms typically associated
with migraine but not included in the IHS
criteria. The symptoms considered specific
for migraine were given two points, and more
unspecific migraine related symptoms one
point. Two points were given for each of the
following premonitory symptoms: craving
for food, yawning, stereotypical mood change
and exceptional tiredness already before the
attacks. One point was given for provocation
of an attack by stress, by missing a meal, by
ingestion of alcohol, chocolate, cheese, or
specifically of red wine. One point was given
for each of paleness during an attack, goose
Table 14. The Aura Index
Type of aura: Points
Any visual 2
Fortification spectra 6
Scotoma 6
Photopsia 4
Speech 4
Sensory 1
Motor 1
Hemisensory 3
Hemiparetic 4
Aura frequency:
1 1
2-10 5
> 10 10
Aura spread 3
Aura duration > 1 min 3
Aura < 60 min before headache 3
Maximum total 50
The total sum of scored points gives the aura index score
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pimples during an attack, feeling cold during
an attack, sweating during an attack, and
tachycardia or bradycardia during an attack.
The index (sum of points given) can range
from 0 (no feature present) to 20 (all fea-
tures present).
4. The index for overall severity of migraine
is designed to reflect the life-time burden of
migraine in relation to the patient in ques-
tion (Table 15). Variables relating to aura are
omitted from the index. The index for over-
all severity of migraine can range from 0 to
50.
4.7. Linkage analysis of four typical
migraine families (Study V)
4.7.1. Subjects
Ten clinically diagnosed migraine patients
with a positive family history of migraine
were selected for the molecular genetic study.
The migraines of the index cases were re-
sponsive to the treatment with sumatriptan,
at the time a novel 5HT
1D
-like receptor ago-
nist (10).  Family information was collected
initially from the description of the clinically
studied index case, after which the question-
naire (FMSQ
o
) was sent to all members of
the family, regardless of whether they had
been classified as affected or non-affected on
the basis of the information from the index
case. All responding family members were
then classified as migraineurs or non-
migraineurs based on the IHS criteria. For
further genetic analysis, four families with
the highest number of affected individuals
were selected (Table 12, Study V; Figure 1).
4.7.2. Methods
Four polymorphic microsatellite markers
(D19S216, D19S221, D19S226, and
D19S215) were analysed to see whether four
migraine families with typical IHS migraine
would show linkage to the FHM locus on
19p13. All of the markers were chosen from
Genethon’s amplifiable marker map (220).
EDTA-blood samples from all available fam-
ily members were collected, and genomic
DNA extracted by standard procedures (219).
The markers were analysed using PCR and
polyacrylamide gelelectrophoresis. PCR re-
actions were performed in multiwell
microtitration plates for 28 cycles as de-
scribed previously (221). One of the primers
was labeled at the 5’ end using 32P-g ATP.
The amplified fragments were size-analysed
by 5% denaturing polyacrylamide gel  (221).
Table 15. The Index for Migraine Severity
Number of lifetime attacks: Points
> 100 12
50-100 8
10-50 4
5-10 2
< 5 1
Headache severity:
unbearable 10
severe 8
moderate 4
mild 1
Headache duration:
> 72 hours 8
2-72 hours 5
< 4 hours 2
Nausea 3
Vomiting 3
Photophobia 3
Phonophobia 3
Aggravation by stress 2
Aggravation by missing a meal 2
Not able to work 4
Maximum total: 50
The total sum of scored points gives the migraine
severity score
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Two point and multipoint linkage analy-
ses were carried out using the MLINK,
ILINK, and LINKMAP options of the LINK-
AGE package (222). The allele frequencies
for all markers were calculated from the
founders and married-in members of the
families. Segregation of the trait was per-
formed with the ILINK option of the LINK-
AGE package. The likelihood was maxim-
ised over penetrance with the disease gene
frequency of 0.08. ILINK provided a
penetrance of 0.436 for homozygous disease
gene carriers, 0.574 for heterozygotes, and
0.001 for homozygous nondisease gene car-
riers. This model closely resembles an auto-
somal dominant inheritance pattern. For the
linkage analyses, we constructed three age-
dependent penetrance classes based on the
age of onset in our family material. For indi-
viduals under 19 years, 20-29 years, and over
30 years, penetrances of 0.35, 0.50, and 0.70
were used, respectively. The phenocopy fre-
quency of 0.024 was used for all age groups.
The maximum penetrance of 0.70 was
adopted since the ILINK result is an average
for all age groups. With these values the
population frequency of genetically affected
individuals would be 0.108, the frequency of
phenocopies 0.020, and the population fre-
quency of all affected individuals 0.128. The
phenocopy frequency was set that high be-
cause two families (1 and 3, Figure 1) had
one married-in migraineur.
4.8. Levels of endothelin-1 in
migraine (Study VI)
4.8.1. Subjects
To study ET-1 in migraine, 31 clinically di-
agnosed migraine patients were chosen (Ta-
ble 12, Study VI). All the participants had 1-
6 migraine attacks per month at the time of
the study. Patients with a history of opiate,
psychotropic drug, alcohol or ergotamine
abuse were excluded, as were patients with
hypertension (diastolic blood pressure > 95
mmHg), ischemic heart disease or other
manifestations of arteriosclerosis. All patients
had also a positive family history of migraine.
4.8.2. Methods
Endothelin-1 (ET-1) was measured during
and between the migraine attacks. The ictal
values were taken as soon as possible after
the beginning of an untreated migraine at-
Figure 1. Pedigrees of the four migraine families analysed
Affected individuals are indicated by filled symbols, deceased individuals with
probable migraine by asterisks. Patients suffering from migraine with aura are
indicated by an A. =male,    =female, /=deceased
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tack; 22 samples, with a mean time of delay
of 4.9 hours (SD 4.2, range 0.8-14.0) were
examined. All patients had by definition mod-
erate or severe headache when the blood
samples were taken. Interictal samples from
18 patients were taken at least 72 hours af-
ter the last migraine attack. Both ictal and
interictal values were recorded for 9 patients.
The blood samples were drawn, with the
patients supine, from the cubital vein. Plasma
was separated from blood drawn into tubes
containing Na
2
EDTA. The plasma was fro-
zen and stored immediately at -20 oC until
assayed for ET-1. Control plasma samples
were obtained similarly from 76 ambulatory,
healthy subjects (41 men, 35 women).
All plasma samples were purified by
Bondelut C18-OH analytical columns
(Analytichem. International, Harbor City,
USA). One millilitre of plasma was acidified
with 4% acetic acid and subjected to columns
prewashed with methanol and distilled wa-
ter. The columns were then washed with dis-
tilled water and absorbed peptide eluded with
40% ethanol in 4% acetic acid. The eluted
fraction was lyophilised and subjected to ET-
1 radioimmunoassay, which was performed
as described earlier (223) using synthetic ET-
1 (Peptide Institute, Barnet, UK) and ET an-
tiserum generated in rabbits with ET-1 cou-
pled to glutaraldehyde to keyhole limpet
hemocyanin (Sigma, St.Louis, LA, USA) as
an immunogen. The antiserum showed
100% cross-reaction with ET-2 and ET-3
(human; Peninsula, London, UK). The an-
tiserum showed < 0.1% cross-reaction with
the 20-50, 74-91, 171-201 sequences of
preproendothelin (Peptide Institute), with big
endothelins 1-38 and 22-38 (human; Penin-
sula), ANP 1-28 (human; Peninsula), angi-
otensin II (Schwarz-Mann, St. Louis, LA,
USA), and arg-vasopressin (Ferring, Malmö,
Sweden).
4.9. Statistical analyses
In Studies I-IV and VI the data were re-
corded and analysed with StatView 4.5 and
5.0 software packages (Abacus Concepts,
Inc., Berkeley, CA, USA, 1996). Addition-
ally, in analyses of agreement (Study I),
StatXact-4 for windows software package
was used (Cytel Software Corporation, MA,
USA, 1999). In Study V LINKAGE package
(222) was used. In the questionnaire-based
studies (Studies II, III, IV), statistical analy-
ses were undertaken for those who had re-
sponded to the particular question, missing
data was not analysed.
In Study I, for validation of FMSQ
FS
,
weighted Cohen’s kappa statistic was used
to test the observed agreement, corrected for
chance (224), between the clinical and ques-
tionnaire diagnosis (step I) and between the
telephone interview and the questionnaire
(step II). A value of > 0.75 was set to indi-
cate strong agreement.
In Studies II and III (the twin studies)
unpaired analysis of variance using Fisher’s
PLSD post hoc test was used to compare the
age of the twins between the diagnostic cat-
egories. The Chi-squared test and Fisher’s
exact test were used for categorical data. The
Mann-Whitney U-test or Kruskal-Wallis one-
way analysis of variance were used for or-
dered categories. An alpha level of 0.05 was
used to indicate statistical significance.
Bonferroni/Dunn correction was used for
multiple comparisons.
In Study IV (the family study) analyses
of variance using Fisher’s PLSD post hoc test
and the Chi-squared test were employed in
relation to continuous variables (the clinical
indices) and category variables (the IHS vari-
ables, prodromal symptoms, provoking fac-
tors, autonomic-nervous-system symptoms),
respectively. An alpha level of 0.05 was used.
In Study V (the linkage study) LOD
(logarithm of odds) score cutoff values of 3
and –2 were used to show and to exclude link-
age, respectively.
In Study VI 95% confidence intervals
were calculated for the ET-1 values and dif-
ferences between the ET-1 values at differ-
ent time points.
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5.1. Validation of study
questionnaires (Studies I-II)
The questionnaires were validated by com-
paring agreement between the questionnaire-
based and interview-based diagnoses.
5.1.1. The Finnish Migraine-Specific
Questionnaire for Twins (FMSQ
TW
)
A correct migraine diagnosis could be made
for all the 20 participating migraine patients
purely by means of the questionnaire. Two
patients with migraine without aura would
have been classified as MU according to the
questionnaire. One had vague sensory symp-
toms with headache which, judging by the
clinical interview and using the IHS criteria,
were not migraine aura. The other patient had
had only one IHS aura during her life-time
and thus did not fulfill the IHS frequency
criterion for migraine with aura.
5.1.2. The Finnish Migraine-Specific
Questionnaire for Family Studies (FMSQ
FS
)
The first stage of FMSQ
FS
 validation com-
pared the questionnaire-based diagnoses to
the clinical diagnoses reached by the study
neurologist. The association between these
two sets is shown in Table 16 (Stage I).
All 100 migraine patients were diagnosed
as suffering from migraine on the basis of
their replies to the questionnaire. In two cases,
a distinction between MwA and
MwA+MwoA proved impossible based on
the FMSQ
FS
. Corresponding conditional
probabilities relating to the questionnaire are
shown in Table 17. Results are also shown
with the non-IHS category MU omitted or
recategorised as MwoA. Weighted Cohen’s
Table 16. Association Between the Clinical and the Questionnaire Diagnoses
Stage I MwA  (Q)  MwA+MwoA  (Q) MU (Q)  MwoA (Q) Total
MwA (CL) 7 1 0 0 8
MwA+MwoA (CL) 2 45 8 0 55
MwoA (CL) 0 0 15 20 35
Total 9 46 23 20 98
Stage II MwA (Q) MwA+MwoA (Q) MU (Q) MwoA (Q) NOMIG (Q) Total
MwA (CL) 17 2 0 0 0 19
MwA+MwoA (CL) 3 20 4 0 0 27
MwoA (CL) 0 0 8 14 1 23
NOMIG (CL) 0 0 0 0 25 25
Total 20 22 12 14 26 94
MwA=migraine with aura, MwA+MwoA=migraine with and without aura, MU=migraine with unclassified aura,
MwoA=migraine without aura, NO
MIG
=no migraine, CL=the clinical diagnosis, Q=the questionnaire-based diagnosis
5. RESULTS
38
Table 18. Validation Stage 2: Conditional Probabilities of the FMSQ
FS
 for Different Types of
Migraine
A. Non-IHS category MU omitted
MwA MwA + MwoA MwoA NO
MIG
Sensitivity 0.89 0.83 0.93 1.0
Specificity 0.95 0.97 1.0 0.98
False positive rate 3/20 2/22 0/14 1/26
False negative rate 2/63 4/61 1/69 0/57
Positive predictive value 0.85 0.91 0.0 0.96
Negative predictive value 0.97 0.93 0.99 0.0
B. MU subjects re-categorised as MwoA
MwA MwA + MwoA MwoA NO
MIG
Sensitivity 0.89 0.74 0.61 1.0
Specificity 0.96 0.97 1.0 0.99
False positive rate 3/20 2/22 0/14 1/26
False negative rate 2/74 7/72 9/80 0/68
Positive predictive value 0.85 0.91 1.0 0.96
Negative predictive value 0.97 0.90 0.89 1.0
The FMSQ
FS
-based diagnosis is compared with diagnosis reached on the basis of a telephone interview by a
neurologist, MwA=migraine with aura, MwA+MwoA=migraine with and without aura, MwoA=migraine without
aura, NO
MIG
=no migraine, FMSQ
FS
=the Finnish Migraine-Specific Questionnaire for Family Studies
Table 17. Validation Stage 1: Conditional Probabilities of the FMSQ
FS
 for Different Types of
Migraine
A. Non-IHS questionnaire category MU omitted
MwA MwA + MwoA MwoA
Sensitivity 0.88 0.96 1.0
Specificity 0.97 0.96 1.0
False positive rate 2/9 1/46 0/20
False negative rate 1/66 2/29 0/55
Positive predictive value 0.78 0.98 1.0
Negative predictive value 0.98 0.93 1.0
B. MU subjects re-categorised as MwoA
MwA MwA + MwoA MwoA
Sensitivity 0.88 0.82 1.0
Specificity 0.98 0.98 0.87
False positive rate 2/9 1/46 8/43
False negative rate 1/89 10/52 0/55
Positive predictive value 0.78 0.98 0.81
Negative predictive value 0.99 0.81 1.0
The FMSQ
FS
-based diagnosis is compared with diagnosis reached on the basis of a telephone interview by a
neurologist, MwA=migraine with aura, MwA+MwoA=migraine with and without aura, MwoA=migraine without
aura, FMSQ
FS
=the Finnish Migraine-Specific Questionnaire for Family Studies
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Table 19. Validation Stage 2: Differences Between Diagnoses Reached on the Basis of the Telephone Interview and Diagnoses Reached on the Basis
of Responses to the FMSQ
FS
Patient Age Telephone- Questionnaire- Reason for difference in diagnosis
(years) interview-based based
diagnosis diagnosis
Female 67 MwA (TI) MwA+MwoA (Q) Patient recall imprecise
Female 54 MwA (TI) MwA+MwoA (Q) Patient regularly wakes up with migraine
Female 46 MwA+MwoA (TI) MwA (Q) Patient recall imprecise
Female 29 MwA+MwoA (TI) MwA (Q) Patient recall imprecise
Male 71 MwA+MwoA (TI) MwA (Q) Patient regularly wakes up with migraine
Female 45 MwA+MwoA (TI) MU (Q) Patient failed to report all features of aura in Q
Female 46 MwA+MwoA (TI) MU (Q) Patient failed to report all features of aura in Q
Female 41 MwA+MwoA (TI) MU (Q) Patient failed to report all features of aura in Q
Female 30 MwA+MwoA (TI) MU (Q) Patient failed to report all features of aura in Q
Female 63 MwoA (TI) NO
MIG
 (Q) Patient failed to report all features of headache in Q
Female 32 MwoA (TI) MU (Q) Patient reported unspecified visual symptoms
Female 23 MwoA (TI) MU (Q) Patient reported unspecified visual symptoms
Female 33 MwoA (TI) MU (Q) Patient reported unspecified visual symptoms
Female 50 MwoA (TI) MU (Q) Patient reported unspecified visual symptoms
Female 24 MwoA (TI) MU (Q) Patient reported unspecified sensory symptoms
Male 32 MwoA (TI) MU (Q) Patient reported unspecified sensory symptoms
Female 40 MwoA (TI) MU (Q) Patient had migraine aura only once
Female 65 MwoA (TI) MU (Q) Patient recall imprecise
FMSQ
FS
 = the Finnish Migraine-Specific Questionnaire for Family Studies, MwA=migraine with aura, MwA+MwoA=migraine with and without aura, MU=migraine with unclassified aura,
MwoA=migraine without aura, NO
MIG
=no migraine,  TI=telephone interview, Q=questionnaire
40
kappa statistic for the agreement is 0.94
(95% confidence interval 0.88-1.00; a value
> 0.75 indicates strong agreement) if MU
cases were omitted. When the patients in
the MU category were recategorised as
MwoA subjects, the corresponding value of
weighted kappa is 0.86 (95% confidence
interval 0.77-0.94).
In the second stage of validation, 100
consecutive patients who had returned the
questionnaire were contacted by telephone
to compare the questionnaire- and telephone-
interview-based diagnoses. 94 of the 100
could be reached. Sixty-seven (71.3%) were
women and 27 (28.7%) men. Mean age was
44.6 years (SD 18.0, range 6-80 years).
The association between the telephone
interview and the questionnaire is shown in
Table 16 (Stage II). The specificity of the
questionnaire for migraine was 0.96 (25/26),
and sensitivity was 0.99 (67/68). Correspond-
ing conditional probabilities relating to the ques-
tionnaire and subtypes of migraine are shown
in Table 18. The results are again shown with
the non-IHS category MU either omitted or
recategorised as MwoA. Weighted Cohen’s
kappa statistic for this agreement is 0.97 (95%
confidence interval 0.95-0.99), if the MU cases
were omitted. When patients in the MU cat-
egory were recategorised as MwoA subjects,
the corresponding value of weighted kappa is
0.96 (95% confidence interval 0.93-0.98).
Table 19 presents all participants (18 sub-
jects) whose diagnoses were not exactly the
same based on the questionnaire and the tel-
ephone interview. Also reasons for the dis-
crepancies are suggested.
5.2. Clinical characteristics of
migraine in a population-based twin
sample (Study II)
Clinical characteristics of migraine were ana-
lysed on the basis of the questionnaire replies.
805 of the 1018 possible participants returned
the questionnaire (response rate 79.1%).
This included 349 twin pairs, of which both
co-twins returned the questionnaire (pairwise
response rate 68.6%). The mean age of the
subjects was 44.9 years (SD 6.5, range 36-
68 years).
5.2.1. Characteristics of migraine in
individual co-twins
5.2.1.1. Distribution of diagnostic categories
The participants were placed into the study
categories based on their questionnaire re-
plies or the telephone interview (248 indi-
viduals). Of all the analysed individual co-
twins, 39.9%  (321 individuals) were catego-
rised as MA, 7.2% as MU, 20.6% as MwoA
(166 individuals), 18.5% as HA, and 13.8%
as NoHA.
The mean age was 45.2 (SD 6.6, range
36-62) for MA, 45.3 (SD 7.3, range 36-68)
for MU, 44.0 (SD 5.9, range 36-62) for
MwoA, 45.2 ( SD 6.7, range 36-62) for HA
and 44.8 (SD 6.0, range 36-62) for NoHA.
None of these differences between ages was
statistically significant. Men were signifi-
cantly more likely to be diagnosed as NoHA
compared to women (21.5% vs. 12.2%,
p=0.0069). Women were more likely to be
MwoA, but the difference did not reach sta-
tistical significance (21.8% vs. 14.8%,
p=0.068). All other diagnostic categories
were evenly distributed between the genders,
also MA (women 40.0% vs. men 39.3%).
5.2.1.2. Characteristics of aura
Of the 321 MA twins, 98.4% reported visual
phenomena, 7.8% motor, 28.0% sensory, and
5.3% speech disturbances as their aura. Visual
aura was hemianopia in 31.2% of the twins,
scintillating scotoma in 57.3%, photopsia in
42.1%, and blurring of vision in 34.0%.
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Table 20. Headache Characteristics of the Twins with Migraine with Aura (MA) and Migraine without Aura (MwoA)
All twins p MA twins p MwoA twins p
MA (%) MwoA (%) Women (%) Men (%) Women (%) Men (%)
N=321 N=166 N=268 N=53 N=146 N=20
Lifetime 5-10 7.5 4.8 6.3 13.2 4.8 5.0
frequency 10-49 41.1 39.8 40.7 43.4 41.1 30.0
of headache > 50 50.8 54.2 52.2 43.4 52.7 65.0
Duration < 4 15.3 0 12.7 28.3 0 0
of headache (h) 4-24 60.1 73.5 < 0.01 60.4 58.4 < 0.01 69.9 100 < 0.05
24-72 20.2 26.5 22.4 9.4 30.1 0
> 72 1.9 0 1.9 1.9 0 0
Location of Unilateral 67.3 57.8 < 0.05 70.1 52.8 < 0.05 58.2 55.0
headache
Quality of Pulsating 73.5 75.9 77.6 52.8 < 0.001 77.4    65.0
headache
Intensity Mild 1.6 0 0.4 7.5 0 0
of headache Moderate 27.2 31.9 26.2 32.1 < 0.05 34.9 10.0
Severe 53.1 53.6 53.9 49.1 50.7 75.0
Unbearable 17.5 13.9 18.7 11.3 13.7 15.0
Physical activity Worsened by 70.4 72.3 72.4 60.4 73.3 65.0
Associated Nausea 82.6 92.8 < 0.01 84.0 75.5 91.8 100.0
symptoms Vomiting 42.1 44.0 44.0 32.1 42.5 55.0
of headache Photophobia 83.8 74.1 < 0.05 84.7 79.2 75.3 65.0
Phonophobia 57.9 59.0 60.4 45.3 < 0.05 61.6 40.0
MA=migraine with aura, MwoA=migraine without aura, h=hours; N=number of twins (individuals); only values p <0.05 shown % refers to the percentage of twins with the
particular headache characteristic
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Table 21. Distribution of the Study Diagnoses in Monozygotic (MZ) and Dizygotic (DZ) Twin Pairs
All twin pairs (N=349) MZ pairs (N=107) DZ pairs (N=223)
N % N % N %
MA-MA 66 18.9 20 18.7 41 18.4
MA-MwoA 49 14.0 12 11.2 35 15.7
MwoA-MwoA 22 6.3 6 5.6 15 6.7
MU-MA 16 4.6 4 3.7 10 4.5
MU-MU 7 2.0 4 3.7 2 0.9
MU-MwoA 12 3.4 5 4.7 7 3.1
HA-MA 48 13.8 19 17.8 27 12.1
HA-MU 6 1.7 0 0 6 2.7
HA-MwoA 30 8.6 10 9.3 18 8.1
HA-HA 13 3.7 6 5.6 7 3.1
HA-No HA 13 3.7 4 3.7 8 3.6
NoHA-MA 39 11.2 9 8.4 29 13.0
NoHA-MU 3 0.9 0 0 3 1.3
NoHA-MwoA 17 4.9 5 4.7 12 5.4
NoHA-No HA 8 2.3 3 2.8 3 1.3
HA=headache; MA=migraine with aura; MwoA=migraine without aura; MU=migraine with unclassified aura; NoHA=no headache; MA-MA=both twins have MA; MA-MwoA=one
twin has MA the other MwoA; etc., N=number of pairs. There were 19 twin pairs of unkown zygosity
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5.2.1.3. IHS characteristics of headache
IHS characteristics of headache were com-
pared in MA and MwoA twins to determine
possible differences (Table 20). The dura-
tion of headache was more often brief in MA
compared with MwoA (Mann-Whitney U-
test p=0.007; in MwoA headache lasts over
four hours, by definition). Headache was sig-
nificantly more often unilateral  (p=0.039)
and associated with photophobia (p=0.010)
in MA, whereas nausea was more frequent
in MwoA  (p=0.002). Women with MA had
significantly longer (p=0.001) and more se-
vere attacks (p=0.046), and their headache
was more often unilateral (p=0.014), pulsat-
ing (p=0.0004), and they experienced more
phonophobia (p=0.041) than the men with
MA. There was less variability between the
genders in MwoA, but women had longer at-
tacks (p=0.029).
5.2.2. Characteristics of migraine in twin
pairs
5.2.2.1. Concordance of diagnostic
categories
Of all the 349 twin pairs, 18.9% were con-
cordant for MA (MA-MA pairs) and 6.3%
for MwoA (MwoA-MwoA pairs). If a twin
had MA, the risk for the co-twin also having
MA was 0.47, and the corresponding figures
were 0.28 for MU, 0.29 for MwoA, 0.21 for
HA and 0.18 for NoHA. There were no sig-
nificant differences between MZ and DZ
twins in concordance for the study diagnoses.
A complete distribution of the diagnoses in
all the 349 twin pairs is presented in Table
21.
5.3. Clinical characteristics of
migraine in migraine-concordant
monozygotic twin pairs (Study III)
The clinical characteristics of migraine in
these MZ migraine-concordant twin pairs
were analysed on the basis of the question-
naire replies. There were altogether 51 MZ
migraine-concordant pairs (i.e. each co-twin
returned the questionnaire and was subse-
quently diagnosed as having MA, MU or
MwoA).
5.3.1. Distribution of diagnostic categories
Of the 102 MZ twins, 56 (54.9%) were diag-
nosed as MA, 17 (16.7%) as MU and 29
(28.4%) as MwoA. The mean age of the MZ
twins was 44.5 years (SD 7.2, range 36-68).
It was 44.8 (SD 7.4, range 36-62) for MA,
46.2 (SD 9.7, range 37-68) for MU, and 43.5
(SD 4.7, range 36-52) for MwoA. None of
these differences between ages was statisti-
cally significant. 46 pairs were female, five
male (female to male ratio 9.2:1).
5.3.2. Diagnostic categories in twin pairs
In the 51 MZ migraine-concordant twin pairs,
if one twin had MA, the risk for the co-twin
to have MA as well was 0.71, the correspond-
ing figures being 0.47 for MU and 0.41 for
MwoA. There were 12 MZ twin pairs dis-
cordant for the main migraine subtypes, MA
and MwoA (MA-MwoA pairs). Of these
pairs, 11 were female, 1 male. The distribu-
tion of the study diagnoses differed signifi-
cantly from evenly distributed expected val-
ues, p=0.0064 (Table 22). MA-MA,
MwoA+MwoA, MU-MU were the pairs that
were observed more frequently than ex-
pected.
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Table 22. Distribution of the Study Diagnoses in the 51 Migraine Concordant Monozygotic
Twin Pairs
N %
MA-MA 20 39.2
MA-MwoA 12 23.6
MwoA-MwoA 6 11.8
MU-MA 4 7.8
MU-MU 4 7.8
MU-MwoA 5 9.8
N=number of twin pairs, MA=migraine with aura, or migraine with and without aura, MwoA=migraine without
aura, MU=migraine with unclassified aura, MA-MA pair=both co-twins have MA, MA-MwoA=one co-twin has
MA and the other MwoA, etc.
5.3.3. Characteristics of aura
In the twin pairs concordant for MA (MA-
MA pairs, altogether 40 individuals) 40/40
cases (100%) reported visual auras. One
(2.5%) had motor and 11 (27.5%) sensory
symptoms as an aura.  16 (40.0%) had  nega-
tive scotoma or hemianopia, 28 (70.0%)  for-
tification spectra, 13 (32.5%) photopsia and
13 (32.5%) visual blurring. In the one sub-
ject with motor symptoms the aura was not
hemiparesis. In three individuals the sensory
symptoms were of clearly spreading
hemisensory nature. Two had speech distur-
bances as an aura.
5.3.4. The IHS characteristics of headache
Headache characteristics in the MA and
MwoA categories were compared. Also in-
dividuals in diagnostically different twin
pairs, i.e. MA-MA, MA-MwoA or MwoA-
MwoA pairs, were similarly compared (Ta-
ble 23).
The MA twins had significantly more
short-lived headache attacks (<4 hours,
p=0.014) and more photophobia (p= 0.032),
while the MwoA twins had more nausea
(p=0.025). The headache of the MA twins in
the MA-MA pairs did not differ significantly
from the headache of the MwoA twins in
the MwoA-MwoA pairs in any respect (fre-
quency, severity, duration, associated fea-
tures, etc.). The MA twins in the MA-MA
pairs had significantly more photophobia than
the MwoA twins in the MA-MwoA pairs
(p=0.023). The MA twins in the MA-MwoA
pairs had more often unilateral headache com-
pared to their MA counterparts in the MA-
MA pairs (p=0.037). The MA twins did not
differ significantly from the MwoA co-twins
in any respect within the MA-MwoA pairs.
The MA co-twins in the MA-MwoA pairs
had significantly more often unilateral and
pulsating headache than the MwoA co-twins
in the MwoA-MwoA pairs (p=0.009 for uni-
lateral headache and p=0.047 for pulsating
headache). The MwoA twins in the MA-
MwoA and MwoA-MwoA pairs did not dif-
fer significantly from one another. Life-time
frequency of headache, overall duration of
headache and intensity of headache did not
differ significantly between any of the diag-
nostic groups.
Concordance of the different aura and
headache features was also compared (Table
24). The distribution of unilateral headache
differed significantly between the groups
(p=0.033). The MA-MwoA pairs had signifi-
cantly more often unilateral headache when
compared separately to both the other groups
(p=0.043 in comparison with the MA-MA
pairs and p=0.025 in comparison with the
MwoA-MwoA pairs). Corrected with the
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Table 23. Headache Features in the Monozygotic Migraine Concordant Co-twins
Headache All MA All MwoA MA twins MA twins MwoA twins MwoA twins
variables twins twins in MA-MA in MA-MwoA in MA-MwoA in MA-MwoA
pairs  pairs pairs  pairs
% of twins % of twins % of  twins % of twins % of twins % of twins
N=56 N=29 N=40 N=12 N=12 N=12
Lifetime 5-10 7.1 3.4 7.5 0.0 0.0 0.0
frequency 10-49 42.9 37.9 47.5 25.0 33.3 33.3
of headache >50 50.0 58.6 45.0 75.0 66.7 66.7
Duration of < 4 17.9 0.0 17.5 16.7 0.0 0.0
headache (h) 4-24 55.4 75.9 60.0 41.7 58.3 83.3
24-72 23.2 24.1 20.0 33.3 41.7 16.7
> 72 1.8 0.0 0.0 8.3 0.0
Unilaterality Unilateral 66.1 55.2 55.0 91.7 75.0 33.3
Pulsating quality Pulsating 85.7 72.4 80.0 100.0 83.3 66.7
Intensity Mild 1.8 0.0 0.0 8.3 0.0 0.0
of headache Moderate 17.9 20.7 22.5 8.3 25.0 25.0
Severe 55.4 62.1 55.0 58.3 66.7 58.3
Unbearable 23.2 17.2 20.0 25.0 8.3 16.7
Physical activity Worsened by 75.0 65.5 77.5 66.7 66.7 58.3
Associated Nausea 83.9 100.0 80.0 91.7 100.0 100.0
symptoms Vomiting 41.1 51.7 37.5 50.0 50.0 50.0
of headache Photophobia 83.9 62.1 82.5 83.3 50.0 58.3
Phonophobia 55.4 55.2 55.0 50.0 66.7 41.7
MA=Migraine with aura, MwoA=Migraine without aura, MA-MA pair=both co-twins have MA, MA-MwoA pair=one co-twin has MA and the other MwoA, MwoA-MwoA pair=both twins
have MwoA, h=hours, N=number of co-twins (individuals), % refers to the percentage of twins with the particular headache characteristic,       = Chi-square or Fisher’s exact
test p < 0.05
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Table 24. Distribution of Clinical Characteristics in Migraine with Aura (MA) and Migraine without Aura (MwoA) Concordant and Aura
Discordant Monozygotic (MZ) Twin Pairs
MA concordant MZ pairs Aura discordant MZ pairs MwoA concordant MZ pairs
Aura or headache N=20 N=12 N=6
characteristics
Neither twin Discordant Concordant Neither twin Discordant Concordant Neither twin Discordant Concordant
with the for the for the with the for the for the with the for the for the
characteristic characteristic characteristic characteristic characteristic characteristic characteristic characteristic characteristic
Type of  aura:
Any visual aura 0 0 20 Not applicable No aura
Hemianopia or scotoma 9 6 5 Not applicable No aura
Fortification spectra 0 12 8 Not applicable No aura
Photopsia 10 7 3 Not applicable No aura
Blurring of vision 9 9 2 Not applicable No aura
Hemiparesis 20 0 0 Not applicable No aura
Hemisensory aura 17 2 1 Not applicable No aura
Speech disturbance 20 0 0 Not applicable No aura
Characteristics of headache:
Over 50 lifetime attacks 6 10 4 1 5 6 0 4 2
Duration of headache 4-72 h 2 4 14 0 3 9 0 0 6
Unilateral headache 4 10 6 0 4 8 3 2 1
Pulsating headache 2 4 14 0 2 10 0 4 2
Moderate or severe headache 0 1 19 0 1 11 0 0 6
Aggravation by physical activity 1 7 12 2 4 6 1 3 2
Associated symptoms:
Nausea 2 4 14 0 1 11 0 0 6
Vomiting 9 7 4 4 4 4 2 2 2
Photophobia 1 5 14 2 4 6 1 3 2
Phonophobia 6 6 8 3 4 5 3 1 2
N=number of twin pairs, MA=migraine with aura, or migraine with and without aura, MwoA=migraine without aura. Discordant pairs differ significantly from the concordant
pairs in unilateral headache (Mann-Whitney U-test, p<0.05)
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Bonferroni/Dunn method for multiple com-
parisons, the difference remains significant
between MA-MwoA and MwoA-MwoA.
5.3.5. Ascertainment of zygocity of twins
All aura-discordant twin pairs (MA-MwoA
pairs) were genotyped to confirm their zy-
gocity as MZ. Zygocity was confirmed as MZ
in all 12 pairs (verifying the validity of the
previously used questionnaire).
5.4. Clinical characteristics of
familial migraine with and without
aura (Study IV)
Clinical characteristics of familial migraine
were analysed on the basis of the question-
naire replies. Of the 1000 consecutive mi-
graine sufferers who had returned the ques-
tionnaire, 730 were women, 270 men. 94 of
the patients (60 women, 34 men) failed to
indicate whether they suffered from both
MwA and MwoA, so an unambiguous study
diagnosis was therefore possible in the case
of 906 subjects who were analysed further.
5.4.1. Age of the patients
The mean ages of the patients in the diag-
nostic categories were 53.0 (SD 11.6, range
19-74) years for Eqv, 41.0 (SD 17.0, range
9-84) years for MwA, 44.4 (SD 16.8, range
8-87) years for MwA+ MwoA, 42.1 (SD
18.5, range 6-90) years for MU and 40.6 (SD
19.2, range 5-90) years for MwoA. The mean
age of the Eqv subjects was statistically sig-
nificantly greater than in the other catego-
ries (p=0.001 in relation to MwA subjects,
p=0.012 in relation to MwA+MwoA sub-
jects, p=0,002 in relation to MU subjects,
and p=0.0004 in relation to MwoA subjects).
The mean age of the MwA+MwoA subjects
was significantly higher than of the MwoA
subjects (p=0.012). No other difference be-
tween the categories was significant. The
observed statistical age differences between
the study categories, although statistically
significant, are not considered clinically rel-
evant in a questionnaire-based study.
5.4.2. Distribution of the diagnostic
categories
Participants were placed into the study cat-
egories based on the questionnaire replies or
the clinical interview (182 individuals). Of
the 906 analysed patients, 29 (3.2%) were
diagnosed as Eqv, 102 as MwA (11.1%), 373
as MwA+MwoA  (40.6%), 186 as MU
(20.3%) and 216 as MwoA  (23.5%) (Figure
2). The distribution of the diagnoses differed
significantly between women and men
(p<0.0001). Men were more likely to be di-
agnosed as MwA or MwoA and women as
MwA+MwoA.
5.4.3. Characteristics of aura
Table 25 shows the occurrence of different
types of migraine aura among the patients,
and the values calculated for the aura indi-
ces. The mean aura index was 33.0 (SD 9.0)
for MwA, and 30.0 (SD 9.0) for
MwA+MwoA. The aura index was statisti-
cally significantly higher in MwA subjects
than in MwA+MwoA subjects (p=0.0003).
Figure 3 shows the occurrence of the visual
aura in the patients. Aura in the MU category
does not meet the IHS criteria, and the MU
patients were thus not analysed.
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Table 25. Clinical Characteristics of Familial Migraine: Migraine Aura
MwA (%) MwA+MwoA (%) MU (%)
N=102 N=373 N=186
Type of aura:
Any visual aura 100.0 99.7 60.8
Hemianopia 68.6 53.1 7.0
Scintillating scotoma 73.5 65.1 7.5
Photopsia 47.1 55.0 23.7
Blurring of vision 52.9 48.0 31.7
Speech disturbance 45.1 37.8 25.3
Any sensory aura 52.0 44.8 33.9
Any motor aura 28.4 26.0 10.2
Hemisensory aura 43.1 37.5 19.9
Hemiparetic aura 25.5 22.8 7.5
MwA MwA+MwoA MU
Aura index:
Index score, total (SD) 33.0 (9.0) 30.0 (9.0) 9.8 (7.4)
Index score, women (SD) 34.1 (9.2) 30.5 (9.2) 10.2 (7.5)
Index score, men (SD) 31.0 (9.5) 27.9 (7.9) 8.1 (6.9)
MwA=migraine with aura, MwA+MwoA=migraine with and without aura, MU=migraine with unclassified aura,
MwoA=migraine without aura, N=number of patients, SD=standard deviation, % refers to the percentage of
patients with the particular aura characteristic
Figure 2. Distribution of Diagnostic Migraine Categories in Study IV
Eqv=migraine equivalent, MwA=migraine with aura, Mwa+MwoA=migraine with and
without aura, MU=migraine with unclassified aura, MwoA=migraine without aura
Eqv MwA Mwa+MwoA MU MwoA
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Figure 3. Migraine Patients with Visual Aura in Finnish Migraine Families (Study IV)
Patients with different proportions of attacks with visual aura
(0% aura never, 100% aura in every attack)
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5.4.4. IHS characteristics of headache
Tables 26 and 27 show the IHS variables of
headache. The p values relate to distribution
variables between the four diagnostic
categories. The categories were not com-
pared pair-wise. The mean IHS score was
7.1 (SD 2.4) for MwA, 8.3 (SD 1.6) for
MwA+MwoA, 7.9 (SD 1.6) for MU, and 7.4
(SD 1.5) for MwoA. The mean IHS score
was statistically significantly higher for
MwA+MwoA than for MwA (p<0.0001),
MU (p=0.0063) and MwoA (p<0.0001). The
mean IHS score was also significantly higher
for MU than for MwA (p=0.0003) or MwoA
(p=0.002). The mean IHS score for MwA
and MwoA did not differ significantly.
5.4.5. Migraine-associated features
Table 28 shows variables which are unre-
lated to the IHS criteria, but are often de-
scribed by migraine sufferers. The distribu-
tion of these variables differed significantly
between the four diagnostic categories. The
Eqv category was not analysed. Again, no
pair-wise comparisons were undertaken. The
mean value of the index of migraine-associ-
ated characteristics was 4.7 (SD 3.9) for
MwA, 7.4 (SD 3.8) for MwA+MwoA, 6.5
(SD 3.7) for MU and 5.0 (SD 3.0) for
MwoA. Data on 2 patients were missing. The
indices were therefore calculated for 875
patients. The difference between MwA
+MwoA and the other categories was statis-
tically significant (p<0.0001 compared with
MwA, 0.0036 with MU and <0.0001 with
MwoA). MU had statistically significantly
more migraine-associated features than MwA
(p<0.0001) and MwoA (p<0.0001). The dif-
ference between MwA and MwoA was not
statistically significant.
%
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Table 26. Clinical Characteristics of Familial Migraine: Distribution of IHS Characteristics
of Headache within Study Categories
MwA (%) MwA+MwoA(%) MU (%) MwoA (%) p
N=102  N=373 N=186 N=216
Lifetime frequency of
migraine attacks
< 5 7,8 0,5 0,0 0,0
5-10 14,7 4,8 7,0 6,9
10-50 21,6 21,7 25,3 23,6 < 0,0001
50-100 22,5 23,1 23,1 26,9
> 100 30,4 47,2 39,2 36,1
(data missing) (2.9) (2.7) 5.4) (6.5)
Duration of  typical
migraine attacks
< 4 hours 32,4 12,9 10,2 19,4
4-72 hours 60,8 79,4 79,0 75,9 < 0,0001
> 72 hours 4,9 7,5 8,1 2,3
(data missing) (2.0) (0.3) (2.7) (2.3)
MwA=migraine with aura, MwA+MwoA=migraine with and without aura, MU=migraine with unclassified aura,
MwoA=migraine without aura, N=number of patients, SD=standard deviation, % refers to percentage of patients
with the characteristic, p-value refers to distribution between the four migraine categories, no pair-wise compari-
sons have been undertaken.
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Table 27. Clinical Characteristics of Familial Migraine: Distribution of IHS Characteristics
of Headache within Study Categories
MwA (%)  MwA+MwoA (%) MU (%) MwoA (%) p
N=102 N=273 N=186 N=216
Unilateral headache 63,7 75,3 67,7 56,5 < 0,0001
Pulsating headache 64,7 77,7 69,9 63,0 < 0,0001
Headache intensity unbearable 34,3 41,0 37,6 25,0
Headache intensity severe 34,3 43,7 40,3 49,5 < 0,0001
Headache intensity moderate 20,6 13,7 21,0 23,6
Headache intensity mild 6,9 0,8 0,5 0,9
Aggravation by physical activity 66,7 78,6 77,4 73,6 < 0,05
Associated nausea 70,6 86,3 83,3 81,5 < 0,0001
Associated vomiting 49,0 58,4 55,9 48,6 < 0,0001
Associated photophobia 83,3 93,6 82,3 76,9 < 0,0001
Associated phonophobia 73,3 83,4 74,7 64,8 < 0,0001
MwA=migraine with aura, MwA+MwoA=migraine with and without aura, MU=migraine with unclassified aura,
MwoA=migraine without aura, % refers to percentage of patients with the characteristic, N=number of patients
p-value refers to distribution between the four migraine categories, no pair-wise comparisons have been undertaken
Data was missing for unilateral headache in 2.9% of patients in the MwA category, MwA+MwoA 0.3%, MU 1.6%,
MwoA 0.5%; for pulsating headache: MwA 2.9%. MwA+MwoA 0 %, MU 1.6%, MwoA 0.9%; for headache
intensity: MwA 3.9%, MwA+MwoA 0.8%, MU 0.5%, MwoA 0.9%; for aggravation by physical activity: MwA
21.6%, MwA+MwoA 12.3%, MU 16.7%, MwoA 17.6%; for nausea: MwA 2.0%, MwA+MwoA 0%, MU 0%,
MwoA 0.5%; for vomiting: MwA 2.0%, MwA+MwoA 0%, MU 0.5%, MwoA 0%; for photophobia: MwA 2.0%,
MwA+MwoA 0%, MU 1.6%, MwoA 0%; for phonophobia: MwA 2.0%, MwA+MwoA 0%, MU 1.6%, MwoA 0%
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Table 28. Clinical Characteristics of Familial Migraine: Distribution of Associated Features
of Migraine within Study Categories
MwA (%) MwA+MwoA (%) MU (%) MwoA (%) P-value
N=102 N=372 N=186 N=321
Prodromal symptoms:
Craving for food 7.8 18.0 13.4 5.1 < 0.0001
Yawning 21.6 41.9 34.9 25.5 < 0.0001
Stereotypical 19.6 31.2 22.0 12.0 < 0.0001
mood change
Unusual tiredness 33.3 51.6 53.2 38.0 < 0.0001
Provoking factors:
Stress 73.5 90.6 76.3 76.4 < 0.0001
Missing a meal 46.1 73.2 74.7 66.7 < 0.0001
Alcohol 30.4 55.6 45.7 38.4 < 0.0001
Periods 36.4 55.3 46.3 40.6 < 0.0001
Chocolate 9.8 14.2 8.6 4.2 < 0.0001
Cheese 5.9 9.1 5.9 3.7 < 0.01
Redwine 6.9 7.5 3.2 2.3 < 0.001
Symptoms related to
activation on ANS:
Paleness 54.9 79.1 72.0 65.3 < 0.0001
Goose pimples 32.4 41.0 36.6 29.2 < 0.0001
Feeling cold 21.6 27.9 28.0 22.2 < 0.01
Sweating 4.9 13.9 14.0 9.3 < 0.01
Tachycardia 20.6 37.5 27.4 17.1 < 0.0001
Bradycardia 3.9 8.6 10.2 3.2 < 0.01
MwA=migraine with aura, MwA+MwoA=migraine with and without aura, MU=migraine with unclassified aura,
MwoA=migraine without aura, ANS=Autonomic nervous system, IHS=International Headache Society, % refers
to percentage of patients with the characteristic, P-value refers to distribution between the four migraine
categories, N=number of patients
Data was missing in < 2% of questionnaires for each presented migraine characteristic, except in 8.4% of
questionnaires for provocation of attacks by alcohol (10.8% in MwA, 5.6% in MwA+MwoA, 11.8% in MU and
6.5% in MwoA)
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Table 29. Clinical Characteristics of Familial Migraine: the Clinical Indices
                                                MwA                                    MwA+MwoA                             MwoA
women men women men women men
                                  mean (SD)                                mean (SD)                                   mean (SD)
The aura index 34.1 (8.7) 31.0 (9.5) 30.5 (9.2) 27.9 (7.9) 0 0
The index for IHS-headache 7.2 (2.4) 6.8 (2.5) 8.5 (1.5) 7.5 (1.7) 7.5 (1.5) 7.1 (1.5)
The migraine-associated- 5.4 (4.3) 3.4 (2.7) 7.9 (3.6) 5.5 (3.8) 5.2 (3.0) 4.6 (3.2)
characteristics index
The migraine severity index 32.4 (10.2) 30.6 (11.1) 37.8 (8.3) 34.2 (8.5) 33.5 (7.2) 31.7 (7.3)
MwA=migraine with aura, MwA+MwoA=migraine with and without aura, MU=migraine with unclassified aura,
MwoA=migraine without aura, SD=standard deviation. The aura index and the index for IHS-headache could be
calculated for all 102 MwA, 373 MwA+MwoA and 216 MwoA patients; The migraine associated-characteristics-
index for 102 MwA, 371 MwA+MwoA and 216 MwoA patients (data missing for 2 patients in these categories)
The migraine severity index for 98 MwA, 363 MwA+MwoA and 202 MwoA patients (data missing for 30
patients)
Figure 4. The index Score for Migraine Severity
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MwA=migraine with aura, MwA+MwoA=migraine with and without aura, MU=migraine
unclassified aura, MwoA=migraine without aura
95 % confidence interval bars shown
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5.4.6. Overall migraine severity
The mean migraine severity index was 31.8
(SD 10.5) for MwA, 37.1 (SD 8.4) for
MwoA+MwoA, 34.7 (SD 8.9) for MU and
32.9 (SD 7.2) for MwoA (Figure 4). Data
on 38 patients in these categories were miss-
ing, the indices were calculated for 839 pa-
tients. The Eqv category was not analysed.
The mean migraine severity index was sta-
tistically significantly higher for
MwA+MwoA than for MwA (p<0.0001),
MU (p=0.0031) and MwoA (p<0.0001)
(95% confidence intervals are shown in Fig-
ure 4). The index was also statistically sig-
nificantly higher for MU than for MwA
(p=0.0059) or MwoA  (0.0361). The migraine
severity index did not differ significantly be-
tween MwA and MwoA. Table 29 shows all
clinical indices in the family study.
5.5. Linkage analysis of four
typical migraine families (Study V)
Linkage analysis was performed in four Finn-
ish migraine families (Figure 1) to study
whether these families were linked to the re-
ported FHM locus on 19p13 (1).
The pairwise linkage data are shown in
Table 30. All of the markers displayed LOD
scores of <-2 at a recombination fraction of
0.0. The exclusion map of the chromosomal
region based on the multipoint analyses of
four markers flanking the FHM locus is given
in Figure 5. Altogether a region of 50 cM
(centiMorgans) could be excluded (LOD
score <-2) as the migraine locus in the four
Finnish families studied. For ‘affecteds only’
analysis, all penetrances were divided by 1000
and pair-wise lod scores were calculated. All
of the markers resulted in negative lod scores
(Table 30).
Figure 5. Exclusion Map of the FHM region in Four Finnish Migraine Families
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5.6. Levels of endothelin-1 in
migraine (Study VI)
Ictal and interictal ET-1 values were meas-
ured to study possible differences between
ictal and interictal states in the migraineurs,
and to compare migraine patients with healthy
control subjects.
The mean interictal ET-1 value was 5.3
pg/ml (SD 1.8) and ictal value 6.4 pg/ml (SD
3.9). The mean acute (blood sample taken =
2 h after onset of attack) ET-1 was 8.4 (SD
3.5) and subacute (sample taken later during
attack) 5.0 (SD 3.6). The difference between
the interictal values of the migraineurs and
the control subjects was 1.5 pg/ml (95% con-
fidence interval 0.8 to 2.2). The change be-
tween interictal and ictal values for patients
with both values (n = 9, ET-1 ictal - ET-1
interictal) was -1.7 pg/ml (95% confidence
interval -3.5 to 0.2). The difference between
mean acute and interictal values was 3.1 pg/
ml (95% confidence interval 1.0 to 5.2). Ta-
ble 31 summarises the main results. Gender
differences in ET-1 were not analysed be-
cause there were only two men in the study.
For reference, in our laboratory the mean
plasma ET-1 of healthy subjects is 3.8 pg/
ml (SD 1.3; n = 76, age 21-54, range 0.7 -
5.5 pg/ml, no sex differences).
During the migraine attacks ET-1 value
depended on the time elapsed from the start
of the attack to the time of sampling (Figure
6). The highest values were detected during
the first two hours after the start of an at-
tack. There was no significant difference in
ET-1 values in patients with moderate or
severe headache. Only two patients had aura
during their attack and thus attacks with and
without aura could not be compared. The
acute ET-1 value was 11.0 pg/ml in both pa-
tients with aura.
Table 30. Pairwase Linkage Data for Chromosome 19 Markers
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Table 31. Levels of Endothelin-1 (ET-1) in Migraine Patients
Ictal and interictal ET-1 values Number of subjects Mean SD Std. Error 95% confidence interval
in migraine pg/ml pg/ml
ET-1 interictal 18 5.3 1.8 0.4 4,4 to 6,2
ET-1 ictal 22 6.4 3.9 0.8 4,7 to 8,1
ET-1 control 76 3.8 1.3 0.2 3,5 to 4,1
ET-1 acute 9 8.4 3.5 1.2 5,7 to 11,1
ET-1 subacute 13 5.0 3.6 1.0 2,8 to 7,1
ET-1 interictal - ET-1 control means compared 1.5 0,8 to 2,2
ET-1 ictal - ET-1 interictal ( paired ) 9 -1.7 2.4 0.8 -0,2 to -3,5
ET-1 acute - ET-1 interictal ( means ) means compared 3.1 1.0 to 5,2
ET-1 acute - ET-1 subacute ( means ) means compared 3.5 0,3 to 6,7
Acute=blood sample taken=2 h from attack onset, subacute= blood sample taken later during attack, SD=standard
deviation, Std.Error=standard error
Figure 6. Endothelin-1 Values in the Course of a Migraine Attack
Time elapsed from the beginning of a migraine attack to sample (hours)
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5.7. Summary of clinical characteristics of familial migraine (Studies II-IV)
The results of Studies II, III and IV are compared in Figures 7-10. Figure 7 compares the
diagnostic categories, Figures 8-9 the characteristics of migraine aura, and Figure 10 the
characteristics of migraine headache.
Figure 7B. Distribution of the Diagnostic Migraine Categories in Study IV
Eqv=migraine equivalent, MwA=migraine with aura, MwA+MwoA=migraine with and without
aura, MU=migraine with unclassified aura, MwoA=migraine without aura
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Figure 7A. Distribution of the Diagnostic Migraine Categories in Studies II–IV
MA=migraine with aura, or migraine with and without aura, MU=migraine with unclassified
aura, MwoA=migraine without aura
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Figure 8A. Visual Aura in Finnish Twins Suffering from MA in Studies II and III
MA=migraine with aura, or migraine with and without aura, MZ=monozygotic
Figure 8B. Visual Aura in Patients with MwA or MwoA+MwoA in Finnish Migraine Families in
Study IV
MA=migraine with aura, MwA+MwoA=migraine with and without aura
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Figure 9A. Speech, Sensory and Motor Type of Aura in Finnish Twins Suffering from MA in
Studies II and III
MA=migraine with aura, or migraine with and without aura, MZ=monozygotic
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Figure 9B. Speech, Sensory and Motor Type of Aura in Patients with MwA or MwA+MwoA in
Finnish Migraine Families in Study IV
MwA=migraine with aura, MwA+MwoA=migraine with and without aura
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Figure 10. The IHS Characteristics of Headache in Finnish Twins (Studies II, III) and
Migraine Families (Study IV)
Clinical features of migraine headache as a function of zygosity and diagnosis:
a) Upper figure, left hand side: genetically identical twin pairs concordant for migraine with
aura (MA). Right hand side: corresponding pairs with migraine without aura (MwoA).
b) Lower figure, left hand side: patients in Finnish migraine families with exclusively mi-
graine without aura (MwoA), MwA+MwoA: patients with both aural and non-aural migraine
attacks.
Figure 10 A. The IHS Characteristics of Headache in Finnish Twins Suffering from MA or
MwoA in Studies II and III
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Figure 10 B. The IHS Characteristics of Headache in Finnish Migraine Families in Study IV
MwA=migraine with aura, MwA+MwoA=migraine with and without aura, MwoA=migraine without aura
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Since the discovery of the FHM gene (1, 2)
molecular genetic research on migraine has
been extensive. FHM, a relatively distinct
clinical entity, has been shown to be geneti-
cally heterogenous with at least three differ-
ent genes involved (225). The complexities
of the FHM teach important lessons for stud-
ies involving the more common forms of mi-
graine, migraine with and without aura. Ge-
netically different types of migraine, although
each meeting the current criteria for migraine,
are likely to exist. This means that meticu-
lous clinical analysis looking for subgroups
of migraine is required before molecular ge-
netic analyses can be undertaken. The
number of patients and blood samples needed
to locate additional liability genes for migraine
can be expected to be very high. Methods
that allow cost-effective participation of hun-
dreds of patients is required, making office-
based studies impractical. Thirdly, while a
random search for migraine genes can be
expensive and frustrating, a candidate gene
approach is another relevant strategy for the
studies: in the breakthrough study of FHM,
the co-localization of the CADASIL gene in
the same chromosome, speeded up the mo-
lecular genetic process (1). Thus, studies in-
volving possible candidate genes are impor-
tant.
These three topics are addressed in the
present work. Tools for conducting cost-ef-
fective diagnoses of migraine are created,
clinical characteristics of migraine in Finn-
ish twins and Finnish migraine families are
analysed, and studies concerning the FHM
gene (CACNA1A) and ET-1 as possible can-
didate genes for migraine with and without
aura are carried out.
The FMSQ
TW
 and the FMSQ
FS
Careful clinical planning and validation of the
diagnostic tools and methods to be used is a
necessity in any medical project. Both the
disease under study and the projected study
population have to be accounted for. In the
present studies development of the question-
naires and their pretesting were done in close
collaboration with the migraine patients and
their family members. The participants were
asked to take active part in the process. This
helped to translate the questions into the lan-
guage of the study population and avoided
many possible misunderstandings and inac-
curacies. These pretesting methods have
been shown to add accuracy to question-
naire data (226). Subsequent validation stud-
ies showed that the work paid off with the
questionnaire-based diagnoses having excel-
lent agreement with the clinical interview-
based diagnoses in the projected target popu-
lation, migraine families (Table 18). Earlier
Rasmussen and colleagues have strongly, and
justifiably, criticised the validity of question-
naire data in headache research (44, 59).
Their conclusion was that migraine can be
ruled out with a questionnaire but that all other
results have to be interpreted with care (44).
The major difficulty has been poor response
rates (44). In the present studies, the response
rates (75-80 % in the twin studies) are good
and demonstrate that, although quite exten-
sive, the questionnaires have been well ac-
cepted by the study population.
The diagnostic categories of the
study
The IHS has succeeded well in its effort to
standardise operational criteria for migraine
all over the world (23, 38). Also in the present
study the IHS classification was found to be
practical, and most participants could be clas-
sified according to the criteria. The use of
the non-IHS category MU, migraine with
unclassified aura, throughout the present
work is necessary for several reasons. It is
6. DISCUSSION
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often difficult, even in a direct interview, to
assimilate the various experiences and de-
scriptions given by patients concerning aura
and aura-like symptoms. Some pain-associ-
ated features can easily be incorrectly clas-
sified as aura, and some important aspect
may be forgotten or ignored by the patient
or the physician. To help in relation to this
distinction the MU category was added for
patients with such unclassifiable, but poten-
tially important, symptoms. Woods et al.
(1994) used positron emission tomography
(PET) to study a patient during an attack of
migraine without aura with unspecified visual
symptoms, and found spreading oligemia
(109), which is widely thought to be con-
sistent with migraine aura (227) and should
not exist in migraine without aura (228). Thus
the IHS criteria might be too restrictive and
in some cases result in a pathophysiologically
unsatisfactory classification placing a patient
with migraine with aura into the migraine-
without-aura category. For genetic linkage
studies, the high specificity of the migraine
diagnosis is more important than high sensi-
tivity. Indeed, the specificity figures of
FMSQ
FS
 are excellent (Table 18) and the ap-
plication of the MU category will further as-
sist in differentiating between migraine with
and without aura.
The study population, Finnish twins
and migraine families
The chosen setting of two distinct target
populations allows one to study, and com-
pare, migraine in the general population, and
in a more clinical cohort, the migraine fami-
lies. The Finnish Twin Cohort (217), from
which the studied twins come from, is rep-
resentative of the isolated population of Fin-
land, and as such provides an exceptional
opportunity for genetic studies of migraine
(229). In analysing the twin data (Studies II
and III) some important aspects related to
patient selection have to be emphasised. Twin
pairs (MZ, DZ, or of unknown zygocity) con-
cordant for a headache problem were in-
cluded in the studies. Thus, the traditional
method of comparing MZ twins to DZ does
not apply: both the MZ and DZ twin pairs
were similarly selected to begin with, thus
abolishing possible zygocity-based differ-
ences. This selection strategy was chosen
to cost-effectively identify sibling pairs for
future molecular genetic studies, and, what
is important for the present work, this strat-
egy does not impair observations on clinical
characteristics of migraine in the population-
based twins. Especially the rare MZ MA-MA
and MwoA-MwoA pairs can be considered
to be interesting when hereditary migraine is
discussed. Another matter related to patient
selection is that twins taking part in a parallel
hypertension study were not included. While
this probably does not affect the presented
clinical characteristics of migraine, in the
future molecular genetic studies the omis-
sion could have consequences, especially in
relation to the vascular aspects of migraine,
and it thus has to be accounted for.
In the family study, index cases were
selected from consecutive migraine patients
attending two outpatient neurological clinics.
Patients with an exceptionally prominent fam-
ily history of migraine were chosen, regard-
less of their aura status, or other character-
istics of their attacks. Thus, no bias towards
MwA or MwoA exists due to the selection
method. Subsequently all first degree rela-
tives of the index case were included in the
study. While the index cases are probably
biased towards having severe migraine, their
family members are not, which makes the
data more balanced. Overall, the presented
migraine families can thus be considered to
represent well typical familial migraine in
Finland.
Clinical characteristics of familial
migraine in Finland
In all the presented studies, clinical analysis
naturally relies heavily on the IHS criteria.
The criteria are applied and explored both in
relation to aura and headache. Despite this,
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other features of migraine are not forgotten,
especially Study IV pays attention to several
migraine-associated features not defined by
the IHS. Figures 7-10 summarize the key
observations during the studies.
Distribution of diagnostic study
categories in familial migraine
More than half of all patients with familial
migraine (altogether 1545 individuals, Stud-
ies II–IV) had migraine with aura (the MA,
MwA, MwA+MwoA categories). This is
much more than the usual notion that 15%
of all migraine patients have migraine with
aura, and even more than the one third re-
ferred in a recent review by Ferrari (4). Thus,
in familial migraine, aura is much more preva-
lent than usually believed. This is in agree-
ment with the view that the hereditary com-
ponent in migraine with aura is stronger than
in migraine without aura (181). Another key
observation concerning migraine with aura
is that the frequency distribution of patients
with different proportions of attacks with
aura is clearly not a normal distribution (Fig-
ure 3). On the contrary, opposite ends of the
spectrum stand out. Thus patients with ex-
clusively migraine with aura and exclusively
migraine without aura can be identified. This
is also in agreement with previous literature.
Population-based epidemiological studies
have for years underlined the importance of
differentiating migraine with aura from mi-
graine without aura (58, 59, 230).
Also differences between genders have
been observed (Figure 2). Men belong rela-
tively more often to the pure MwA or MwoA
categories than do women. Women have
more often both kinds of attacks, and thus
belong to the MwA+MwoA category. This
observation could have implications for fu-
ture studies. Families with men migraineurs
having solely MwA or MwoA could be easier
to find than families with female migraineurs
belonging always to the same category. This
could assist in sorting out families into more
homogenous groups and reduce genetic het-
erogeneity. It is possible that in the future
migraine classification will be based on the
underlying molecular genetic predisposition,
and the clinical importance of detailed fam-
ily history of migraine will increase.
Migraine aura
The occurrence of the different aura symp-
toms in familial migraine (Figures 8-9) is es-
sentially similar to that described by Russell
and Olesen in a population-based clinical
study using the IHS criteria (26). As expected
visual aura and fortification spectra are the
hallmarks of migraine with aura. This is true
also for the rare MZ MwA-concordant twin
pairs, which can in a way be taken to present
pure hereditary migraine with aura. Russell
and Olesen found that speech disturbance,
sensory and motor aura were present in 31,
18 and 6 % of migraineurs, respectively. The
figures from the present study are not com-
parable, because questionnaire data can not
be compared to a clinical interview regard-
ing these aura symptoms. Despite this, the
obvious difference between twins and fam-
ily members is interesting (Figures 8-9).
Twins from a sample representing the gen-
eral population (Studies II and III) report
clearly less speech, sensory and motor mani-
festations than the family members in the
questionnaires. This suggests differences be-
tween clinical (all index cases of families had
contacted a neurologist for advice regarding
their migraine) and population-based migraine
(the twins were included regardless of
whether they had contacted a doctor regard-
ing their migraine). Of note is also that none
of the MwA-concordant MZ twins had
hemiparetic symptoms. Thus, if one surveys
a population-based twin registry in search of
monozygotic twin pairs concordant for IHS
migraine, one ends up with typical migraine
with visual aura, but with no hemiparetic
symptoms. Also hemisensory symptoms are
very rare. This might suggest that typical IHS
migraine with aura is distinct from FHM, and
the proposed pathophysiological similarity of
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FHM and migraine with aura (96) needs to
be re-evaluated.
The presented observations have patho-
physiological implications. Scintillating
scotoma, not hemiparesis, is the characteris-
tic feature in familial migraine. Scintillating
spreading scotoma with positive and negative
features can also be considered the best ex-
trapolation to represent spreading depression
in patients. Molecular genetic studies of a large
sample of patients or sibling pairs (or families
if possible) with typical build up of the IHS
fortification spectra will be one of the next
steps in the analysis of the significance of
spreading depression in migraine. Clearly, twin
pairs concordant for this characteristic can
be identified. Among the many possible can-
didate genes underlying the spreading migraine
aura in humans, there could be genes coding
for connexin proteins, which are subunits of
gap-junctions (231) and have also been asso-
ciated with spreading depression (231, 232)
and, at least in theory, with induction of neu-
rovascular changes responsible for the pain
in migraine (121).
Migraine headache
Figure 10 summarises observations regarding
migraine headache in familial migraine. There
is a clear trend in the distribution of unilateral
headache, nausea, vomiting and photophobia
in the twin pairs. Genetically identical MZ
subjects in MA concordant twin pairs are rela-
tively more characterised by unilateral head-
ache and photophobia. Correspondingly, pa-
tients in MZ twin pairs concordant for MwoA
have more nausea. Clinically, in terms of di-
agnosis and treatment, the differences shown
are probably not important, but pathophysio-
logically they merit attention. For example, in
terms of molecular genetic analysis, subgroups
with MwA with prominent photophobia and
strictly unilateral headache and MwoA with
prominent nausea can be targeted when typi-
cal migraine with and without aura, respec-
tively, are analysed. In Sardinia, a subgroup
of patients with prominent nausea (and yawn-
ing) has already been associated with a
dopamine receptor gene (DRD2) (198). A
similar trend (unilateral headache and photo-
phobia in MwA and nausea in MwoA) can be
seen in the families, but the difference is not
so clear. In addition the MwA+MwoA cat-
egory clearly stands out in having the most
typical migraine headache in all respects. In
light of these differences, it was unfortunate
that the twin questionnaire did not differenti-
ate MwA from MwA+MwoA. This shortcom-
ing will be corrected in an extension study of
the family members of MwA- and MwoA-
cordordant twin pairs.
Comorbidity of migraine with and
without aura
The key observation in the family study was
that patients with MwA+MwoA differed in
their attack characteristics from both their
pure MwA and MwoA counterparts. They are
the ones with several attacks and numerous
associated features (Table 28).
This is not surprising, compared to the
MwA patients, because the IHS criteria de-
fine only the aura phase and many patients
with mild headache fulfill the criteria for IHS
migraine with aura. What is surprising, is that
the headache of the MwA+MwoA patients
is also more typical than of the MwoA sub-
jects, who were diagnosed entirely based on
the IHS-defined characteristics of vascular
headache. Thus, the complete migraine (32,
233) does not belong to either of the pure
types, i.e. MwA or MwoA, but to those with
both kinds of attacks.
This suggests that the relationship of
migraine with and without aura could be ex-
pressed as a continuum, shown in Figure 11.
This theory would also explain some of the
differences in opinion between clinicians and
epidemiologists on the comorbidity of mi-
graine with and without aura (234, 235).
Thus, in clinical populations, MwA+MwoA
patients with severe attacks stand out, while
in population-based studies, MwA and
MwoA patients are easily identified.
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This relates also to the main result of the
twin studies, the migraine-subtype-discord-
ant monozygotic twin pairs. It can be hy-
pothesised that these twins, in the migraine
spectrum of Figure 11, would be located
between MwA+MwoA and MwoA patients.
Thus, genetic predisposition would be inter-
mediate for the aura, and environmental or
acquired factors would eventually decide
whether attacks with aura should appear, with
the co-twins differing in these influences de-
spite their identical genotype.
Exclusion of the FHM locus as a
predisposing locus in four Finnish
migraine families
In study V we applied methods that test if
the locus identified on chromosome 19p
would contribute to the more common forms
of familial migraine with and without aura.
The linkage analyses resulted in negative LOD
scores (< -2). These exclusion results are,
however, highly dependent on the assump-
tion, that the disease is due to a single major
gene with dominant inheritance. In complex
diseases the affection status is probably
caused by many interacting genes. There-
fore we performed also affecteds only analy-
sis, where only affected individuals have in-
fluence on linkage data. Also these analyses
resulted in negative LOD scores. Thus, ac-
cording to our results there is less than 1:100
chance that the 19p13 region, linked to FHM,
is involved in migraine in our four families.
Consequently, it seems that locus heteroge-
neity exists between different types of mi-
graine.
These results reinforced our clinical no-
tion that a difference between FHM and mi-
graine with and without aura actually exists
also genetically. Secondly, the diverse distri-
bution of migraine with and without aura in
these families helped to guide the develop-
ment of the eventual study questionnaire, in
which much attention is paid to differentiate
between migraine with and without aura.
Figure 11. Hypothesis: Comorbidity of  Migraine with and without Aura
MwA=Migraine with aura, MwA+MwoA=Migraine with and without aura, MwoA=Migraine
without aura
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ET-1 in migraine patients
The recent migraine research has focussed
especially on the neuronal mechanisms (93),
partly ignoring the vascular side and nerve-
blood vessel interaction of migraine. NO
(117) and ET-1 (17, 118) are molecules that
could well mediate some vascular aspects
of migraine. Both are vasoactive and have
been shown to influence the membrane po-
tential of cerebral blood vessels (236, 237),
which in turn influences the vascular tone.
The vascular tone of cerebral vessels, at a
given point of time, could well affect the tem-
poral sensitivity of the vasculature to the
migraine generator residing in the brain stem
(85). Thus, the central activation (brainstem,
hypothalamus) could be modified markedly
by the periphery.
The original report on ET-1 changes in
migraine came from Finland (17). The results
of the present study confirm the observation
that ET-1 levels are elevated early during
migraine attacks (17, 118) and, in addition,
interictal values in migraineurs are higher
than in normal controls. This suggest that ET-
1 might be involved both in the predisposi-
tion to migraine (elevated interictal values),
and in the characteristics of the attacks (el-
evated acute values). The relationship be-
tween migraine aura and ET-1, a potent va-
soconstrictor, is naturally interesting in re-
gard to the old vasoconstriction-vasodilata-
tion hypothesis of migraine (16) and in re-
gard to the observed high ET-1 values early
after onset of migraine in the present study.
On the other hand, it has been shown that
bosentan, an ET-1 antagonist, is not effec-
tive in migraine (119) and, furthermore, ET-
1 does not seem to be involved in spreading
depression (238). Despite these reports, sev-
eral aspects make further studies of ET-1 ap-
pealing. In the present study two subjects had
aura before ET-1 was measured, and both had
very high (11.0 pg / ml) values. It could well
be that the presence of aura would explain
these high values.
In addition, as Studies II-IV have shown,
patients with MwA, MwA+MwoA and
MwoA are clinically distinct and should be
defined and compared also in studies dealing
with ET-1. This was not done in the present
study. ET-1 could well be hypothesised to
be relatively more important in migraine with
aura, and thus make up some of the spec-
trum presented in Figure 11. In addition, ET-
1 could have at least a modifying role in some
special situations related to migraine. In
antiphospholipid syndrome, also associated
with migraine (239, 240), elevated ET-1 lev-
els have been shown to correlate with arte-
rial thrombosis and strokes (241). Thus, ET-
1 could be one of the factors that occasion-
ally contribute to migraine-related strokes
(111).
However, ET-1 is only one of many fac-
tors that affect cerebral vascular tone (242)
at a given time point. Especially the temporal
interplay of the potent vasodilator NO and
the vasoconstrictor ET-1 is interesting in the
discussion on migraine pathophysiology.
Comparison of serially taken ET-1 and NO
values in attacks with and without aura be-
tween a statistically adequate number of pure
MwA and MwoA patients could be one of
the next steps in the evaluation of the even-
tual importance of ET-1 in migraine patho-
physiology.
Future considerations
The clinical characteristics of familial mi-
graine in Finland, presented here, will serve
as the foundation for molecular genetic stud-
ies of migraine in the future. Clearly, in the
study population, migraine with aura domi-
nates over migraine without aura, suggest-
ing indirectly a stronger inherited component
to migraine with aura. Thus, migraine with
aura will be targeted in extension studies. The
MZ-migraine-concordant twin pairs show
that, in addition to genes, also acquired fac-
tors modify the basic migraine characteris-
tics; genetically identical twin pairs concord-
ant for migraine but discordant for aura can
be identified. These environmental confound-
ing influences have to be accounted for also
in genetic studies. The presented data indi-
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cate that migraine with and without aura are
different entities, but with very frequent co-
occurrence. The relationship between the
entities seems to be more of a continuum
than a clear-cut difference. Based on this,
the correct distinction between patients with
migraine with aura and migraine without aura
is essential when predisposing genes for mi-
graine are sought. The presented linkage data
indicate that genetic heterogeneity exists be-
tween FHM and migraine with and without
aura. The common forms of migraine are
likely of multifactorial origin. One of many
candidate genes that could have an impact
on the clinical characteristics and differences
between migraine with and without aura is
ET-1.
The overall conclusion reached here is
that familial migraine is a diverse syndrome
with both clinical and genetic heterogeneity.
It is likely that several subgroups of migraine,
such as FHM, can be identified within IHS-
defined migraine with and without aura. It is
likely that pathophysiological and genetic
mechanisms will differ between these sub-
groups. It appears that one has to move from
studying groups of patients to studying
groups of families with very stereotypical
migraine throughout the whole family before
new predisposing genes for migraine can be
identified. This demands large population-
based studies with accurate case ascertain-
ment and detailed analysis of migraine. The
combined use of national twin registries and
validated migraine-specific questionnaires
can greatly assist in the clinical analysis of
migraine before molecular genetic methods
will take the next step forward.
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This thesis presents clinical observations on
familial migraine in Finland during the first
years of the Finnish Migraine Gene Project.
The eventual goal of the project is to identify
predisposing genes for migraine with and
without aura.
Two questionnaires, developed for the
analysis of familial migraine, the Finnish Mi-
graine-Specific Questionnaire for Twin Stud-
ies (FMSQ
TW
) and the Finnish Migraine-Spe-
cific Questionnaire for Family Studies
(FMSQ
FS
), were validated by comparing the
questionnaire-based diagnoses to the diag-
noses based on a clinical interview. All 20
migraine patients taking part in the valida-
tion study of FMSQ
TW
 were correctly diag-
nosed as migraineurs. In the validation study
of  FMSQ
FS
, agreement between the FMSQ
FS
-
based and clinical interview-based migraine
diagnoses was 0.97 (Cohen’s weighted
kappa). The sensitivity of FMSQ
FS
 for mi-
graine was 0.99, and specificity 0.96.
Clinical characteristics of migraine were
analysed in 321 twins suffering from mi-
graine with aura, or migraine with and with-
out aura, (MA) and 166 twins suffering from
migraine without aura (MwoA) using a com-
bination of a mailed questionnaire and tel-
ephone interview. Unilateral headache
(p<0.05) and photophobia (p<0.05) were
more typical for migraine with aura, while
nausea was more typical for migraine with-
out aura (p<0.05). Also the duration of head-
ache in migraine without aura was longer than
in migraine with aura (p<0.01). There was
no statistically significant difference in the
age of onset, menstrual provocation or pro-
dromal symptoms between MA and MwoA.
Clinical characteristics of migraine were
analysed in 51 migraine-concordant monozy-
gotic (MZ) twin pairs using a validated
mailed questionnaire. All 20 pairs with MA
were concordant for visual aura and 19 for
moderate or severe headache intensity, while
all 6 pairs with MwoA were concordant for
headache duration of 4 to 24 hours, moder-
ate or severe headache intensity, and nau-
sea. The 12 mixed pairs (one twin with MA
and the other with MwoA) had more often
unilateral and pulsating headache compared
to both the MA and the MwoA pairs. All in
all, individual MA twins had more photophobia
(p<0.05) and MwoA twins more nausea
(p<0.05).
Clinical characteristics and co-occur-
rence of migraine with aura (MwA) and mi-
graine without aura (MwoA) were deter-
mined in 1000 migraine patients belonging
to 210 Finnish migraine families, using the
FMSQ
FS
. 906 patients were able to indicate
whether they suffered from migraine with
aura (MwA), migraine with and without aura
(MwA+MwoA) or MwoA, and were ana-
lysed further. Of these patients, 3.2% had
experienced migraine aura without headache
(Eqv), 11.1% MwA, 40.6% MwA+MwoA,
23.5% MwoA and 20.3% migraine with aura-
like symptoms not meeting the IHS criteria.
The MwA+MwoA patients had statistically
significantly more severe attacks, more typi-
cal headache and more prodromal symptoms
than the MwA or the MwoA subjects.
Four polymorphic microsatellite mark-
ers (D19S216, D19S221, D19S226, and
D19S215) were analysed to study whether
four migraine families with typical IHS mi-
graine would show linkage to the FHM lo-
cus on 19p13. All of the markers displayed
LOD scores < -2 at a recombination fraction
of 0.0. Also ‘affected only’ analysis resulted
in negative LOD scores. Thus, it is highly
unlikely that the 19p13 region is involved in
migraine in these four typical migraine fami-
lies.
The plasma levels of ET-1 (endothelin-
1) in 31 migraine patients were studied dur-
ing and between migraine attacks. The mean
interictal and ictal values were 5.3 pg/ml
(SD1.8) and 6.4 pg/ml (SD 3.9), respectively.
The ictal values were markedly elevated at
the beginning of the migraine attack and de-
clined to interictal or even a lower level later
7. SUMMARY AND  CONCLUSIONS
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in the course of an attack. The interictal val-
ues of migraineurs were significantly higher
than those of control subjects. Only two of
the patients had an aural attack, ET-1 in these
attacks was high (11.0 pg/ml).
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1. The Finnish Migraine-Specific Questionnaire for Twins (FMSQ
tw
) and the Finnish
Migraine-Specific Questionnaire for Family Studies (FMSQ
FS
) were valid and prac-
tical for use in the twin and family studies of migraine.
2. There are differences in the clinical characteristics of migraine between migraine
with and without aura. The headache phase in migraine with aura is shorter and does
not always fulfill the IHS criteria for migraine headache. Unilateral headache and
photophobia are relatively more typical for migraine with aura, while nausea is more
typical for migraine without aura. Migraine with aura predominates in the popula-
tion-based cohort.
3. Co-twins of migraine-concordant monozygotic twin pairs can have different types
of  migraine. Differences in clinical characteristics between twins with and without
aura are not determined entirely by genes.
4. Migraineurs of Finnish migraine families had frequently both migraine with and with-
out aura. The co-occurrence of both types was most usual in the migraineurs with
the most severe attacks.
5. Familial migraine in the studied families was not linked to the FHM locus in 19p13,
suggesting genetic locus heterogeneity in migraine with and without aura.
6. The interictal values of ET-1 in migraineurs were higher than in normal controls.
The levels of ET-1 increased even further early during the migraine attacks. The
liability to migraine and attack characteristics could be modified by ET-1. The ET-1
gene can be considered one of the candidate genes for migraine, and particularly for
migraine with aura.
Recalling the specific aims of the present study, the results can be
summarised as follows:
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APPENDIX 1.
QUESTIONS  CONCERNING  THE  IHS  CRITERIA  OF  HEADACHE
How long do your headache attacks last
without medication (usually):
1 less than 4 hours
2 4-24 hours
3 24-72 hours
4 over 72 hours
How long do your headache attacks last with
medication (usually):
1 less than 4 hours
2 4-24 hours
3 4-72 hours
4 over 72 hours
What is the quality of headache during the
attacks (usually):
1 pain is on one side
2 pain is on both sides
1 it is pulsating / throbbing
2 it is steady
1 it is mild
2 it is moderate
3 it is severe
4 it is unbearable
Can you work / take care of your tasks during
the attacks:
1 yes 2 no
How does physical effort affect headache:
(for example climbing stairs, busy walking or
such normal activity)
1 makes it worse
2 makes it milder
3 has no effect / can not say
During your attacks, do you have:
1 nausea
2 vomiting
3 sensitivity to light
4 sensitivity to sound
5 visual disturbances
6 one sided sensory numbness or
motor weakness
87
QUESTIONS  CONCERNING  THE  IHS  CRITERIA  OF  VISUAL  AURA:
[ Questions concerning hemiparetic or
hemisensory symptoms were asked in the
same way ]
Preceding the attacks, do you have.
1 visual disturbances lasting
several minutes
(for example zigzag patterns,
clear double vision,
repeatedly flashing lights,
deficiency in your visual fields)
2 difficulties to speak
3 one sided sensory numbness or
motor weakness
If you have experienced visual disturbances
preceding the attack, is it:
1 Deficiency in your visual fields
2 scintillating zigzag pattern
3 sparks, stars in your visual field
4 blurring, undulating vision
5 other visual disturbance:
How fast does this symptom develop and
how long does it last:
1 it is at it’s worst or maximum
intensity in less than 1-2  minutes
2 it worsens or spreads over 4
minutes
1 it lasts less than one minute
2 it lasts less than one hour, but
over a minute
3 it last over an hour
1 it disappears fully in 24 hours
2 it does not disappear fully
How are visual disturbances and headache
connected in time:
1 headache follows the
symptoms in less than one hour
2 headache follows the
symptoms later
3 headache and the symptoms
occur at the same time
4 headache comes first
5 no headache occurs
How many headache attacks with these kind
of aura symptoms (symptoms preceding the
attacks) have you had during your lifetime:
1 one
2 2 or more
3 over ten
Please explain in your own words all the
symptoms preceding headache:
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APPENDIX 2. The Finnish Migraine-Specific Questionnaire for
Family Studies (FMSQ
FS
)
Dear addressee!
A study has been started in Meilahti Hospital which aims to investigate the heredi-
tary nature of migraine. This way the knowledge of migraine will be improved
and as there will be more information, improved medication and treatments can
be developed for the symptoms of those with migraine.
There is a person in your family having migraine and therefore we would like you
to participate in our study regardless of whether or not you have migraine.
The study is in two parts:
1. You are requested to fill in and return the questionnaire (a pre-paid and pre-
addressed return envelope is enclosed)
2. You are requested to visit your own health centre or private doctor for a blood
test. A referral to a blood test will be enclosed to the questionnaire (the health
centre will know from the referral which tests they should do) We request that you
contact your private doctor or health centre before you go to the blood test.
Naturally, the study is absolutely confidential. You will be informed of the results
when the study is completed.
Should you have any questions about the study, please contact:
Markus Färkkilä Mikko Kallela
Docent Resident
Physician in charge of the research
Helsinki University Central Hospital (HUCH)/
Meilahti Hospital / Outpatient Department of Neurology
Tel: 4711
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PLEASE ANSWER THE FOLLOWING QUESTIONS ABOUT HEAD-
ACHE AND MIGRAINE
- THE QUESTIONS CONCERN ALL THE HEADACHES YOU HAVE
HAD DURING YOUR LIFE
- PLEASE ANSWER EVEN IF YOU NO LONGER HAVE HEADACHES
- PLEASE ANSWER ACCORDING TO THE INSTRUCTIONS ON THE
NEXT PAGE EVEN IF YOU HAVE NEVER HAD ANY HEADACHES
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QUESTIONNAIRE FOR THE GENEALOGICAL STUDY OF MIGRAINE:
Name: ...................................................................................................
Date of birth: .........................................................................................................
Address: ..............................................................................................
Telephone: ............................   Work: .................................................
E-mail: ..................................................................................................
Who is the relative, who asked you to participate in the study:
....................................................................................................................................
In what way are you related?
....................................................................................................................................
Which one of the following describes your state in relation to head-
aches best
• I have hardly any headaches at all and there
have not been headaches before either (  )
• I have headaches (or have had headaches)
sometimes (  )
• My head often feels strange and heavy like
there was pressure inside (  )
• I have a headache approximately once a month (  )
• I have headaches weekly (  )
• I have a headache almost every day (  )
If you do not have headaches and have not really had them before,
please go straight to section 24
Please answer the following questions, however, if YOU HAVE DISTURBING
HEADACHES, OR HAVE HAD DISTURBING HEADACHES AT LEAST SOMETIMES.
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1. I would estimate that I have had headaches
during my life:
Possible childhood headaches are also included, please check the most
appropriate  alternative
Never (  )
(please move on to section 24)
less than 5 (  )
5-10 (  )
10-50 (  )
50-100 (  )
more than 100 (  )
2. At the moment, I have headaches:
for 15 days a month or less (  )
for over 15 days a month (  )
3. Without medication, the headaches
(usually) last:
Or if you always take medication, how long would you estimate they would
last without medication
less than 4 hours (  )
4-72 hours (  )
more than 72 hours (  )
“Without medication, a headache typical of me lasts
(or lasted) for”:
If you always take medication for the headache, please give an estimate of
how long you would think it would last without medication
With medication, the headaches
(usually) last:
less than 4 hours (  )
4-72 hours (  )
more than 72 hours (  )
The longest continuous period that the headaches
have lasted is:
__________________
days
The shortest headaches last:
__________________
hours
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4. The ache is (usually):
one-sided (  )
throbbing or pounding (  )
“the ache is throbbing to he beat of the hearth”
steady (  )
some other kind, what:  ________________________ (  )
5. The intensity of the headaches is (usually):
mild (  )
moderate (  )
severe (  )
unbearable (  )
On a scale of 1 to 10 the headaches are
(usually):
________________
0 = no headache, 10 = the most severe
headache imaginable
Are you usually capable of working / going
to school during the headaches:
the headaches prevent working / going to school entirely (  )
the headaches clearly make working /going to school more
difficult (  )
the headaches do not impede with working / going to
school significantly (  )
I cannot say (  )
 6. Does the ache ever change from one side
to another (if it is one-sided)
yes (  ) no (  )
7. How does physical exercise (e.g. climbing up stairs
or a similar normal exercise) affect the headaches:
makes them worse (  )
does not affect (  )
makes them better (  )
I cannot say (  )
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8. Do the headaches (at least sometimes) involve:
nausea (  )
vomiting (  )
sensitivity to light (  )
sensitivity to sounds (  )
9. Do you see ”after images” in connection
with the headaches as you close your
eyes:
yes (  ) no (  )
10. Which one of the features of the headache bothers you the most
(do not choose more than one feature):
the throbbing of the headache (  )
the intensity of the headache (  )
the nausea and / or vomiting
associated with the headaches (  )
the sensitivity to light and /or
sounds associated with the
headaches (  )
otherfactor,what?  _________________ (  )
If necessary, please explain in more detail:
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
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11. Are the headaches (at least
sometimes) preceded by:
• VISUAL DISTURBANCE yes (  ) no (  )
(e.g. serrate optical phenomenon, pronounced
double vision, recurring flashes of light, flashing
lights or colours, visual field defect)
• SPEECH DIFFICULTY yes (  ) no (  )
......................
• SENSORY DISTURBANCE OF THE LIPS OR TONGUE
(e.g. TINGLING OR NUMBNESS)
yes (  ) no (  )
• ONE-SIDED SENSORY DISTURBANCE yes (  ) no (  )
(e.g. TINGLING OR NUMBNESS) in the face+arm or arm+leg or
face+arm+ leg)
......................
• ONE-SIDED MUSCULAR WEAKNESS yes (  ) no (  )
(e.g.  in the face+arm or arm+leg or face+arm+leg)
......................
• SENSORY DISTURBANCE OF ALL 4 yes (  ) no (  )
  EXTREMITIES
• MUSCULAR WEAKNESS IN ALL 4 yes (  ) no (  )
  EXTREMITIES
......................
• VERTIGO yes (  ) no (  )
(the world is spinning, seems clearly to be moving)
yes (  ) no (  )
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12. Are the headaches repeatedly
preceded by: some of the following symptoms, which
indicate to you that the headaches are coming, even though your head
does not hurt yet?
Unusual HYPERENERGY (  )
RESTLESSNESS, DIFFICULTY OF CONCENTRATION (  )
“CRAVING” FOR A CERTAIN FOODSTUFF (  )
e.g. chocolate, other sweets etc.
Please explain in more detail:
........................................................................................
........................................................................................
Unusual feeling of THIRST (  )
Unusually frequent YAWNING (  )
Clear change of MOOD (  )
repeatedly in the same way
Depression (  )
Nervousness (  )
Irritation, ill temper (  )
Good mood
Please explain in more detail: (  )
........................................................................................
........................................................................................
Difficulty in FOCUSING THE EYES (  )
Pronounced, unusual TIREDNESS,
POWERLESSNESS (  )
“dead beat”, “dead-tired” before the headaches
SENSITIVITY TO LIGHT (before the headaches) (  )
SENSITIVITY TO SOUND (before the headaches) (  )
FEELING OF COLD, FREEZING
SWEATING, COLD SWEAT
FEELINGS IN THE NECK
e.g. pain, stiffness, tension, etc.
Please explain in more detail:
........................................................................................
........................................................................................
OTHER PRODORMAL SYMPTOM yes (  )         no (  )
Another symptom is:
........................................................................................
........................................................................................
None of the above (  )
96
13. Do the headaches ever involve:
Visual disturbance IN BOTH EYES: (  )
AT THE SAME TIMES
Tinnitus (  )
Hearing loss (  )
Ear ache (  )
Pressure in the ears, blocked ears (  )
Other ear symptom (  )
Whatkind ...........................................................................
Vertigo, “the world is spinning like a merry-go-round” (  )
Other kind of dizziness (  )
Clumsiness of hands (  )
Objects keep falling from the hands (  )
Clumsiness of feet (  )
Disturbance of balance,uncertainty of walking (  )
Double vision (  )
Difficulties in swallowing (  )
Stiffness or numbness of the tongue (  )
Numbness of the pharynx (  )
Fits of fainting and unconsciousness (  )
Fever (  )
Confusion (  )
None of the above (  )
97
14. Can the following factors trigger the headaches:
Menstruation (  )
Alcohol (  )
Certain food or a beverage (what?) (  )
........................................................................... ........
Not eating (  )
Forgetting to eat a snack (  )
Physical exercise (  )
Stress (  )
Relieving of stress
e.g. weekend, beginning of holiday (  )
(Even a mild) injury to the head,  “banging one’s head” (  )
Sleeping too long (  )
Staying up, lack of sleep (  )
Change of the climate (  )
Please explain in more detail:
........................................................................... .................
........................................................................... .................
Heat, e.g. hot weather, sauna (  )
Coldness, e.g. cold weather (  )
A bright or a flashing light
Please explain in more detail:
........................................................................... .................
........................................................................... .................
A certain scent or smell (  )
Please explain in more detail:
........................................................................... .................
........................................................................... .................
Does another factor trigger the head aches often (which?)
........................................................................... .................
........................................................................... .................
None of the above (  )
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15. The headache can be alleviated by:
An easy run (  )
Lying down (  )
Turning off the lights (  )
Another factor, which? (  )
........................................................................... .......
........................................................................... .......
16. Hormonal factors affecting the
headaches (for women):
Beginning of menstruation:
increased the headaches (  )
decreased the headaches (  )
had no effect (  )
Menstruation has not started yet (  )
During the last two trimesters of pregnancy the headaches:
got better (  )
got worse (  )
no effect (  )
I have not been pregnant (  )
If necessary, please explain in more detail:
........................................................................... .......
........................................................................... .......
The effect of the cessation of menstruation (menopause):
alleviated the headaches (  )
made the headaches worse (  )
had no effect (  )
Menstruation has not ended yet (  )
The effect of contraceptive pills
alleviated the headaches (  )
made the headaches worse (  )
had no effect (  )
I have never taken contraceptive pills (  )
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17.  Do the headaches often start:
- early in the morning ........ (  )
- in the morning ........ (  )
- before noon ........ (  )
- afternoon ........ (  )
- in the evening ........ (  )
- in the night ........ (  )
- There is no clear connection with the start of the (  )
headaches to the above
- in connection with menstruation (  )
18. Do the headaches involve:
- Abdominal pain (  )
- Diarrhoea (  )
- Constipation (  )
- Flatulence (  )
- Paleness (  )
- “Goose bumps” (  )
- Fingers turn “white” (  )
- Facial flushing (  )
- Dizziness when getting up (  )
- Everything goes black before the eyes when getting up (  )
- Skin feels dry (  )
- Feeling of cold, freezing (  )
- Sweating, cold sweat (  )
- Palpitation (  )
- Slow heartbeat (  )
(pulse is slower than normal)
- Nose “gets blocked” or “is running” (  )
- Tears are “dripping” from the eyes (  )
- Mouth turns dry (  )
- Eyes feel dry (  )
- Clear feeling of malaise (  )
- Clear feeling of weakness (  )
None of the above (  )
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19. How old were you when the headaches started:
younger than 5 years (  )
younger than 10 years (  )
younger than 15 years (  )
younger than 20years (  )
20-30 years (  )
30-40 years (  )
40-50 years (  )
older than 50 years (  )
How old approximately __________  years old
please do not hesitate to state the age according to your best
recollection
20. Has any event in your life (or an
equivalent experience) Increased your
headaches significantly
going to school (  )
studying (  )
working (  )
marriage (  )
birth of the children (  )
divorce (  )
serious illness (  )
head injury (  )
meningitis (  )
other, what? (  )
____________________________________________________
____________________________________________________
serious illness of a family member (  )
certain medication, what? (  )
____________________________________________________
____________________________________________________
None of the above (  )
101
PLEASE DESCRIBE BRIEFLY THE
MOST TYPICAL FEATURES OF YOUR
HEADACHES
1 __________________________________________________________
__________________________________________________________
2 __________________________________________________________
__________________________________________________________
3 __________________________________________________________
__________________________________________________________
DO YOU HAVE MORE THAN ONE
TYPE OF HEADACHE?
YES (  )
NO (  )
PLEASE EXPLAIN IN MORE DETAIL
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
HAS YOUR DOCTOR/PHYSICIAN
DIAGNOSED YOU TO HAVE
MIGRAINE?
YES (  )
NO (  )
I DO NOT KNOW (  )
HAVE YOU EVER HAD AN MRI OF
THE BRAIN PERFORMED?
YES (  )
NO (  )
I DO NOT KNOW (  )
IF YES, WHERE AND WHEN WAS IT PERFORMED?
__________________________________________________________
__________________________________________________________
__________________________________________________________
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21. Medication:
Which medicine is the most efficient on your
headaches:
(please underline the efficient medicinal products, 2
lines under the most efficient one)
- Panadol, Para-Suppo, Para-Tabs
- Acetard, Acetylsalic., Alka-Selzer, Asapor, Aspirin,
Disperin, Primaspan, Migpriv
- Diclometin, Diclomex, Trabona, Voltaren
- Brufen, Bucal, Burana, Ibumetin, Ibusal, Nurofen,
Dexit
- Confortid, Indocal, Indocid, Indometin, Inmetsin
- Ketocal, Ketofen, Ketomex, Ketorin, Orudis
- Alpoxen, Miranax, Naprometin, Naprosyn, Naproxen,
Nycopren, Pronaxen
- Dacam, Felden, Pirom
- Clotam, Tolfen
- Clinoril, Donobid, Novalgin, Ponstan, Surgamyl,
Tilcotil, Toradol
- Norflex, Robaxin, Trancopal
- Dolan, Lobac, Metsapal, Muscotal, Norgesic,
Robaxisal, Somadril
- Aspam, Dolopam, Dolorin
- Indalgin, Panacod, Staralgin, Symptomal
- Anervan, Cafergot, Trimigrin
- Klotriptyl, Limbitrol, Noritren, Saroten, Triptyl
- Imigran, Migmax
- Zomig, Naramig, Maxalt
- some other product, which one:
........................................................................
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22. Targeted drugs for migraine:
Have you ever taken Imigran® or
Migmax® for migraine?
yes (  ) no (  )
Did you take:
a tablet of 50 mg (  )
a tablet of 100 mg (  )
nasal spray (  )
injection (  )
suppository (  )
I do not remember (  )
Would you say that the effect was:
Excellent ............................................................................ (  )
...........
Good ............................................................................ (  )
...........
Moderate ............................................................................ (  )
...........
Poor ............................................................................ (  )
Please explain in more detail
...............................................................................................
...............................................................................................
Did the medication have side yes (  ) no (  )
effects?
If yes, what were they like?
...............................................................................................
...............................................................................................
Have you ever taken Zomig®-, Naramig®
or Maxalt® for migraine?
yes (  ) no (  )
What was the effect of Zomig® like .............................
.........................
What was the effect of Naramig® like .............................
.........................
What was the effect of Maxalt® like .............................
.........................
Please explain in more detail
...............................................................................................
...............................................................................................
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Is one of these new drugs for migraine
clearly better than the others for you?
yes (  ) no (  )
Please explain in more
detail ..........................................................................................
........................................................................................................
23. Has prophylactic medication for
migraine ever been tried on you?
YES (  )
NO (  )
I DO NOT KNOW (  )
IF IT HAS BEEN TRIED, PLEASE TELL WHICH
MEDICATION AND WHAT ITS EFFECT WAS LIKE:
E.G. BETA-BLOCKER, CALCIUM ANTAGONIST, AMITRITYLINE,
VALPROATE, ACETAZOLAMIDE, ETC. (E.G. PROPRAL®, EMCONCOR®,
KLOTRIPTYL  MITE®, SAROTEN®, DEPRAKINE®, ABSENOR®,
DIAMOX®, ÖDEMIN®, ETC.)
........................................................................................................
........................................................................................................
........................................................................................................
........................................................................................................
........................................................................................................
........................................................................................................
........................................................................................................
........................................................................................................
........................................................................................................
........................................................................................................
........................................................................................................
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The following pages deal with the neurological
symptoms of migraine, so called aura. They are
often connected with headache, most commonly
precede it but can also occur without the ache.
In case you have not had visual disturbance,
sensory disturbance, muscular weakness or
speech difficulties of this kind, you can go straight
to section 29.
However, please glance through the next pages to
see if you recognise any of the symptoms. Some of
them are do not always associated with migraine.
If you have had any of these symptoms during your
life, please answer the questions in the next pages.
24
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25. IS VISUAL DISTURBANCE AN AURA
SYMPTOM IN AT LEAST SOME OF
THE HEADACHES?
(a prodormal aura symptom precedes the headaches but it
can sometimes occur simultaneously with the headaches). PLEASE
CHECK THE APPROPRIATE ALTERNATIVES:
* VISUAL FIELD DEFECT (  )
* Flashing “serrate phenomenon” (  )
*“SPARKS”, “STARS” in the visual field (  )
the colour of the sparks is:
............................................
* BLURRING OF VISION, WAVING in the visual field (  )
• OTHER VISUAL DISTURBANCE,  what: ....................
which:
- is at its worst / strongest right away
(less than 1-2 minutes) (  )
- gets worse / expands after more than 4 minutes (  )
- lasts for less than a minute (  )
- lasts for more than a minute but less than 60 minutes (  )
- lasts for more than 60 minutes (  )
- the symptom goes away entirely (  )
- does not go away entirely (  )
- headaches follow the symptom within 60 (  )
minutes
- headaches do not follow the symptom until (  )
later
- headaches and symptom occur
simultaneously (  )
- headaches precede the symptom (  )
Headaches with prodormal symptoms such as these
you have had in your life:
- once (  )
- 2-5 (  )
- 5-10 (  )
- 10-50 (  )
- 50-100 (  )
- more than 100 (  )
Visual disturbance occurs in about ____ % of the
headaches
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Visual disturbance does not always involve headaches (  )
at all
Please explain with your own words what the visual disturbance is like:
THE VISUAL DISTURBANCE INTENDED HERE ARE VISUAL FIELD DEFECTS, SERRATE OPTICAL
PHENOMENA, “SPARKS”, “STARS”, ETC. MERE SENSITIVITY TO LIGHT DOES NOT HAVE TO BE
REPORTED HERE.
_____________________________________________
_____________________________________________
_____________________________________________
_____________________________________________
_____________________________________________
_____________________________________________
Would you say that your migraines involve visual
disturbance:
Always (  )
Most of the time (  )
In about half of the cases (  )
Every now and then (  )
Never (  )
IF ALL ATTACKS DO NOT INVOLVE VISUAL DISTURBANCE:
Is the headache associated with visual disturbance similar to the
headache in migraine attacks without visual disturbance?
The headaches are similar whether there were prodormal
symptoms or not:
Yes (  )
The headache is different depending on the occurrence of
prodormal symptoms:
Yes (  )
Do you ever have headaches involving nausea or pronounced
sensitivity to light with out the said visual disturbance:
Yes (  )          No      (  )
If necessary, please explain with your own words, how
the headaches differ indifferent kind of attacks:
_____________________________________________
_____________________________________________
_____________________________________________
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26.  IS UNILATERAL PARESIS (MUSCULAR
WEAKNESS) AN AURA SYMPTOM IN
AT LEAST SOME OF THE
HEADACHES:
(a prodormal aura symptom precedes the headaches but it can sometimes occur
simultaneously with the headaches).
Yes (  ) Never (  )
IF YES, IS THE PARALYTIC SYMPTOM:
A. ON ONE SIDE OF THE FACE (  )
(“one half of the face is hanging”)
HAS ANYONE EVER MADE A REMARK ON ONE SIDE OF THE FACE
HANGING DURING THE HEADACHES?
YES (  ) NO (  )
B. IN THE FACE AND IN THE UPPER LIMB OF THE (  )
SAME SIDE
IS THE WEAKNESS OF THE UPPER LIMB EVER SO STRONG THAT
COMPRESSIVE FORCE IS CLEARLY REDUCED DURING THE
HEADACHES?
YES (  ) NO (  )
IS THE WEAKNESS OF THE UPPER LIMB EVER SO STRONG THAT THE ARM
CAN COT BE HELD UP NORMALLY DURING THE HEADACHES?
YES (  ) NO (  )
C. IN THE EXTRIMITIES OF THE SAME SIDE (ARM+LEG) (  )
IS THE WEAKNESS OF THE OTHER LEG EVER SO STRONG THAT YOU
ARE NOT ABLE TO WALK NORMALLY OR THAT YOU WALK WITH A LIMP
DURING THE HEADACHES?
YES (  ) NO (  )
Paralytic symptoms such as these associated with
headaches you have had in your life:
- once (  )
- 2-5 (  )
- 5-10 (  )
- 10-50 (  )
- 50-100 (  )
- more than 100 (  )
IMPORTANT: Please describe with your own words what kind of paralytic
symptoms you have or have had and how long the paresis lasts:
_____________________________________________
_____________________________________________
_____________________________________________
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27. IS A CLEAR UNILATERAL SENSORY
DISTURBANCE, NUMBNESS,
TINGLING AN AURA SYMPTOM IN AT
LEAST SOME OF THE HEADACHES:
Yes (  ) Never (  )
IF YES, IS THE SENSORY DISTURBANCE:
A.  ON ONE SIDE OF THE FACE (  )
(“one side of the face turns numb”, “tingles”)
B. IN THE FACE AND THE UPPER LIMB OF THE SAME (  )
SIDE
C. IN THE EXTRIMITIES OF THE SAME SIDE (  )
(ARM+LEG)
HOW LONG DOES THE NUMBNESS (OR TINGLING) LAST USUALLY?
LESS THAN A MINUTE (  )
MORE THAN 4 MINUTES (  )
DOZENS OF MINUTES (  )
HOURS (  )
DAYS (  )
I CANNOT SAY (  )
DOES THE NUMBNESS (OR TINGLING) EVER OCCUR BEFORE THE
HEADACHES
YES (  ) NO (  )
DOES THE NUMBNESS EVER SPREAD SLOWLY FROM THE ARM UP TO
THE UPPER ARM AND FACE, OR DOWN FROM THE FACE TO THE ARM?
YES (  ) NO (  )
SENSORY DISTURBANCE symptoms such as these
associated with headaches you have had in your life:
- once (  )
- 2-5 (  )
- 5-10 (  )
- 10-50 (  )
- 50-100 (  )
- more than 100 (  )
IMPORTANT: Please describe in your own words what
the sensory disturbance is like:
_____________________________________________
_____________________________________________
_____________________________________________
_____________________________________________
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28. IS PRONOUNCED SPEECH
DISTURBANCE AN AURA SYMPTOM IN
AT LEAST SOME OF THE HEADACHES:
Yes (  ) Never (  )
IF YES, WHAT IS THE SPEECH DISTURBANCE LIKE?
The speech is difficult to form, “the tongue is stiff”, “the
speech gobbles”
yes (  ) no (  )
Has such as speech difficulty ever involved pronounced
weakness of one arm
yes (  ) no (  ) I can not tell (  )
Words are forgotten, words and sentences come out
wrong, “the speech is double Dutch”
yes (  ) no (  )
Has such as speech difficulty ever involved clear
weakness of one arm
yes (  ) no (  ) I can not tell (  )
Headaches involving pronounced speech difficulty you
have had in your life:
- once
- 2-5 (  )
- 5-10 (  )
- 10-50 (  )
- 50-100 (  )
- more than 100 (  )
Please describe with your own words:
_____________________________________________
_____________________________________________
HAVE YOU EVER BEEN IN A HOSPITAL OR AT
THE DOCTOR BECAUSE OF THESE
SYMPTOMS OF PARALYTIC, SENSORY OR
SPEECH DISTURBANCES?
Yes (  ) no (  )
If yes, please explain in more detail:
_____________________________________________
_____________________________________________
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29.A.Family History:
Do (did) your parents have migraine:
Mother …………… yes (  ) no (  )    I do not know (  )
Father …………… yes (  ) no (  )    I do not know (  )
Do (did) your siblings have migraine:
No  (  ) I do not know  (  )
Yes  (  )
Who: ...................................................................
...................................................................
...................................................................
...................................................................
...................................................................
How many brothers and sisters do you have:
…………… sisters …………… brothers
Do (did) your children have migraine:
No  (  )  I do not know (  )
Yes (  )
Who: ______________________________________
______________________________________
______________________________________
______________________________________
______________________________________
How many children do you have: Sons ...............…….
Daughters ...............…….
Does (did) your spouse have migraine:
No (  ) I do not know (  ) No Spouse (  )
Yes(  )
Who: ...................................................................
...................................................................
...................................................................
...................................................................
...................................................................
29
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29.B. Family History
Have your parents, siblings or children had
paralytic symptoms:
No (  ) Who:  ..........................................................................
Yes (  ) ....................................................................................
At what age did the paralytic symptoms
appear?
....................................................................................
Have your parents, siblings or children had
dementia or pronounced memory disturbances:
No (  ) Who:  ..........................................................................
Yes (  ) ....................................................................................
At what age did the symptoms appear?
....................................................................................
Have your parents, siblings or children had
unusual tremor:
No (  ) Who:  ..........................................................................
Yes (  ) ....................................................................................
At what age did the symptoms appear?
....................................................................................
Have your parents, siblings or children had
disturbance of balance or unusual clumsiness or has
any of them been in a wheel chair:
No (  ) Who:  ..........................................................................
Yes (  ) ....................................................................................
At what age did the symptoms appear?
....................................................................................
Have your parents, siblings or children had
epilepsy or seizures:
No (  ) Who:  ..........................................................................
Yes (  ) ....................................................................................
At what age did the symptoms appear?
....................................................................................
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30. Previous illnesses:
Do you have or have you had:
- Stroke (or cerebral infarction (  )
- Intracerebral haemorrhage (  )
- Other cerebral circulatory disorder (  )
of what
kind: ________________________________________
- Epilepsy (  )
- Seizure (  )
- Fit of unconsciousness (  )
- Fever convulsion as a child (  )
- Hypertension (  )
- Myocardial infarction (  )
- Symptomatic heart disease (  )
- Cardiac insufficiency (  )
- Atrial fibrillation (  )
- Other cardiac arrhythmia (  )
- Ménièr’s disease (  )
- Eye disease (  )
which: ..................................................................................
- Diabetes (  )
which: ..................................................................................
- Cancer (  )
which: ..................................................................................
- Rheumatic condition (  )
which: ..................................................................................
- Allergy or atopy: (  )
which one : ..........................................................................
- Mental disorder (  )
Depression, severe depression (  )
Anxiety disorder that needed treatment (  )
Panic disorder (  )
Insomnia (  )
Other,  which:  .......................................................................... (  )
- High cholesterol level (  )
- High triglyceride level (  )
- Do you have or have you had some other significant
illness: (  )
which:  ..................................................................................
None of the above (  )
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31. Other factors:
Yes  (  ) no (  )
Have you been taking contraceptive
pills?
for how long:
.....................................................................................
Do you have a tendency to snore loudly? Yes (  ) no (  )
this is asked because snoring sometimes causes headache
Do you smoke? Yes (  )    no (  )
since when and how much:
.....................................................................................
.....................................................................................
How much alcohol do you use:
I hardly use any alcohol at all (  )
Wine: about ............................. glasses a week
Beer: about  ............................. bottles of medium
strength beer a week
Beer: about  ...........................bottles of strong beer a week
Liquor:  ...........................drinks a week
Does alcohol cause symptoms of hangover to you:
(headache, nausea, etc.)
Extremely easily (  )
Easily (  )
Not particularly easily (  )
Hardly at all (  )
How often do you have disturbing headache in
connection with fever (e.g. common flu)
Always (  )
Often (  )
Sometimes (  )
Hardly ever (  )
32. Your latest blood pressure value was
..........  /  .......   mmHg
(systolic / diastolic)
You do not remember but you were told it was :
high  ........................... yes (  ) no (  )
low  ........................... yes (  ) no (  )
normal ........................... yes (  ) no (  )
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33. Do you fingers easily turn white in the
cold
...................… yes (  ) no (  )
Do phenomena ever occur where your
fingers first turn white, then turn blue
and finally red
...................... yes (  ) no (  )
Do you have or have you had a
tendency for travel sickness
yes (  ) no (  )
Please explain in more detail:
.....................................................................................
.....................................................................................
Do you have or have you ever had fits
of vertigo
yes (  ) no (  )
Please explain in more detail:
.....................................................................................
.....................................................................................
116
34. Places of Birth:
What is your place of birth:
...................................................................................................................
...................................................................................................................
What is your mother’s place of birth:
...................................................................................................................
...................................................................................................................
What is your father’s place of birth:
...................................................................................................................
...................................................................................................................
What are your grandparents’ places of birth:
maternal grandmother:
...................................................................................................................
..................................................................................................................._
maternal grandfather:
...................................................................................................................
...................................................................................................................
paternal grandmother:
...................................................................................................................
...................................................................................................................
paternal grandfather:
...................................................................................................................
...................................................................................................................
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36. NEUROLOGICAL SYMPTOMS:
THIS SECTION IS ESSENTIAL FOR THE
STUDY!!!!!
NEUROLOGICAL SYMPTOMS ASSOCIATED WITH MIGRAINE ARE AMONG
OTHERS:
• VISUAL DISTURBANCE: SERRATE OPTICAL PHENOMENA,
DEFECTS OF VISUAL FIELD, HOLES IN THE VISUAL FIELD, ETC.
• SENSORY DISTURBANCE: UNUSUAL TINGLING OR
NUMBNESS IN THE TONGUE, PHARYNX, FACE OR UNILATERAL TINGLING
OR NUMBNESS IN THE EXTREMITIES OR BODY.
• HEARING IMPAIREMENT: WHISTLING OF THE EAR, PRONOUNCED MO-
MENTARY IMPAIREMENT OF ACCURACY OF HEARING, ETC.
• CHANGES IN THE SENSE OF SMELL
• SYMPTOMS OF PARESIS OR MUSCULAR WEAKNESS
• SPEECH DISTURBANCE
• VERTIGO
• DOUBLE VISION
• DIFFICULTY TO SWALLOW
• OTHER SYMPTOM YOU FIND IMPORTANT
IF YOU HAVE HAD SYMPTOMS
MENTIONED ABOVE OR EQUIVALENT TO
THEM, PLEASE DESCRIBE THEM WITH
YOUR OWN WORDS, IF YOU HAVE NOT
ALREADY DONE SO:
• VISUAL DISTURBANCE:
• SENSORY DISTURBANCE:
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• HEARING IMPAIREMENT:
• PARALYTIC SYMPTOMS:
• SPEECH DIFFICULTIES
• DIZZINESS:
Please explain in more detail what the dizziness is like: e.g. uncertainty
while walking, rotative or spinning, etc.
• SOME OTHER SYMPTOM CLEARLY
ASSOCIATERD WITH YOUR
HEADACHES IS:
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36. HAVE SYMPTOMS SIMILAR TO THE ONES
MENTIONED ABOVE OCCURED WITHOUT
THE HEADACHES?
THESE IMPORTANT SYMPTOMS WERE AMONG OTHERS:
• VISUAL DISTURBANCE: SERRATE OPTICAL PHENOMENA,
DEFECTS OF VISUAL FIELD, HOLES IN THE VISUAL
FIELD, ETC.
• SENSORY DISTURBANCE: UNUSUAL TINGLING OR
NUMBNESS IN THE TONGUE, PHARYNX, FACE OR
UNILATERAL TINGLING OR NUMBNESS IN THE
EXTREMITIES OR BODY.
• HEARING IMPAIREMENT: WHISTLING OF THE EARS,
PRONOUNCED MOMENTARY IMPAIREMENT OF
ACCURACY OF HEARING, ETC.
• CHANGES IN THE SENSE OF SMELL
• SYMPTOMS OF PARESIS OR MUSCULAR WEAKNESS
•  SPEECH DISTURBANCE
• VERTIGO
• DOUBLE VISION
• DIFFICULTY TO SWALLOW
• OTHER SYMPTOM YOU FIND IMPORTANT
YES  (    ) NO  (    )
IF YES, PLEASE CIRCLE THE
APPROPRIATE ALTERNATIVE AND, IF
NECESSARY, EXPLAIN IN MORE DETAIL:
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37. SEVERE HEADACHES:
IN ALL, I WOULD ESTIMATE THAT I
HAVE HAD SEVERE HEADACHES IN
MY LIFE:
POSSIBLE CHILDHOOD HEADACHES ARE ALSO INCLUDED
PLEASE CHECK THE MOST APPROPRIATE ALTERNATIVE
NEVER (    )
LESS THAN 5 (    )
5-10 (    )
MORE THAN 10 (    )
MORE THAN 50 (    )
MORE THAN 100 (    )
HEADACHES INVOLVING VISUAL
DISTURBANCE (AURA) I HAVE HAD:
POSSIBLE CHILDHOOD HEADACHES ARE ALSO INCLUDED
PLEASE CHECK THE MOST APPROPRIATE ALTERNATIVE
NEVER (    )
1 (    )
2-5 (    )
5-10 (    )
MORE THAN 10 (    )
MORE THAN 50 (    )
MORE THAN 100 (    )
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How would you advise us to improve this
questionnaire?
Blood Test Included in
the Study:
You will find a referral to a blood test in the
envelope you received. You will have no costs
of the blood test. You can go to the blood test
to a private doctor or a health centre. (In
Tampere region, the health centre will not
take the blood test, so go to a private doctor
instead).
All the necessary information can be found in
the referral, you only need to give the referral
to the personnel of the laboratory.
(the referral explains how the blood test should be taken, where
the laboratory should send it to and where to direct the bill)
After you have filled in the form, you can close
it in the return envelope.
Thank you very much!
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